

# Ocular Melanoma UK

England & Wales · Charity number 1147506

## Details

---

Other names	OCUMEL UK
Status	Registered
Legal form	Charitable company
Company number	08013670
Registered	2012-05-30
Register	<a href="#">View on the Charity Commission register</a>

## Contact

---

Address 139 Langley Road  
Slough  
SL3 7DZ

Phone 01753 357770

Email [info@omuk.org](mailto:info@omuk.org)

Website [www.omuk.org](http://www.omuk.org)

## Activities

---

**Objects:** (1) TO PRIMARILY PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF PEOPLE WITH OCULAR MELANOMA AND THEIR FAMILIES IN THE UNITED KINGDOM THROUGH SUPPORT, INFORMATION, EDUCATION AND PRACTICAL ADVICE. (2) TO SUPPORT RESEARCH INTO OCULAR MELANOMA AND TO PUBLISH THE USEFUL RESULTS.

**Activities:** Patient Advocacy Informational website Dedicated Helpline Peer-to-peer online support Regional patient meetings Annual national conference Health information Funded psychological support E-bulletins International collaboration Support research

## Classification

---

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** Children/young People, Elderly/old People, People With Disabilities, Other Defined Groups, The General Public/mankind

## Geography

- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£180,903	£173,461	-	-
2024-03-31	£149,295	£149,983	-	-
2023-03-31	£129,170	£140,975	-	-
2022-03-31	£72,090	£140,889	-	-
2021-03-31	£211,110	£201,688	-	-

## Trustees

Name	Role	Appointed
Joanne Frye	Chair	2018-06-18
Alison Benjamin		2023-02-23
Charlotte Edwards		2020-03-18
Colin White		2023-03-30
Diana Walker		2026-03-13
NEIL PEARCE		2012-05-04
Robert Davies		2026-01-22

**Ocular Melanoma UK**

England & Wales - Charity number 1147506

---

# Accounts

---

Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

Ocular Melanoma UK

Report and Accounts

31 March 2025

Ocular Melanoma UK

Report and accounts for the year ended 31 March 2025

Contents

	<b>Page</b>
<b>Charity information</b>	1
<b>Trustees' Annual Report</b>	1
<b>Statement of directors' responsibilities</b>	12
<b>Independent Accountant's Report</b>	14
<b><i>Funds Statements:-</i></b>	
Statement of Financial Activities	16
Statement of Financial Activities - Prior Year statement	17
Movements in funds	18
Income and Expenditure account	19
<b>Balance sheet</b>	20
<b>Notes to the accounts</b>	21

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

The Trustees present their Report and Accounts for the year ended 31 March 2025, which also comprises the Directors' Report required by the Companies Act 2006.

#### **Reference and administrative details**

##### ***The charity name.***

The legal name of the charity is:- Ocular Melanoma UK.

The charity is also known by its operating name, Ocular Melanoma UK, previously OcuMel UK (changed in August 2024).

##### ***The charity's areas operation and UK charitable registration.***

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

##### ***Legal structure of the charity***

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

Updated Articles of Association and Special Resolution are dated 20th August 2024

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

##### **The principal operating address, telephone number, email and web addresses of the charity are:-**

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address [info@omuk.org](mailto:info@omuk.org)

Web Address [www.omuk.org](http://www.omuk.org)

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

##### **The Trustees in office on the date the report was approved were:-**

Mr Neil Pearce

Mrs Alison Benjamin

Mrs Joanne Frye - Chair

Mr Colin White

Mrs Charlotte Edwards - Treasurer

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### The following persons served as Trustees during the year ended 31 March 2025 :-

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-

<i>Name</i>	<i>Appointed</i>	<i>Resigned/Retired</i>
Mr Neil Pearce		
Mrs Alison Benjamin		
Mrs Joanne Frye - Chair		
Mr Colin White		
Mrs Charlotte Edwards - Treasurer		

All the trustees are also members of the charity.

#### Objects and activities of the charity

##### ***The purposes of the charity.***

Ocular Melanoma UK is the only UK charity solely dedicated to supporting people affected by ocular melanoma.

Established in 2009, we have been providing connection and compassionate support since 2011, so that anyone receiving this rare diagnosis has somewhere to turn for understanding, practical guidance, and a community that can make a difficult time feel less isolating.

During the 2024/25 financial year, we changed our name from OcuMel UK to Ocular Melanoma UK. The name change was formally registered on 20 August 2024 and was made to improve clarity, ensuring that patients, families, clinicians and stakeholders can more easily recognise the condition we support. This change supports our ongoing work to raise awareness, strengthen understanding, and connect more people affected by ocular melanoma with the right information and support.

We are determined to drive improvements so people can live well with ocular melanoma. This can be a devastating cancer, so we are working to ensure people have access to effective treatments and that clear pathways are in place, all while striving to provide specialist support to people who need it.

##### **What is ocular melanoma?**

Ocular melanoma is a cancer of the eye.

- We know approximately 750 people in the UK will hear they have ocular melanoma each year, and those people are likely to need support.

- We know we have existing patients in the UK living with ocular melanoma who may need support adjusting to life after their diagnosis.

- We also know that one in every two people will hear they need further treatment if the cancer spreads

- We know that no one should face this terrifying time alone.

Ocular melanoma includes two cancers, uveal and conjunctival melanoma. Uveal melanoma includes the iris, choroid or ciliary body. Both types of ocular melanoma can metastasise (spread) to other organs, with the liver typically involved in 90% of uveal melanoma cases.

If ocular melanoma spreads to another organ, it is currently incurable. Some treatments extend life expectancy and improve the quality of life for some patients, but patients can face difficulties accessing these treatments and clinical trials.

Ocular melanoma is usually discovered during a routine eye examination or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects cancer, they should urgently refer the patient to their local ophthalmology department. Should they agree with the concern, they will refer to one of four specialist centres: Glasgow, Liverpool, Sheffield or London.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

#### **Why is Ocular Melanoma UK needed?**

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming that patients frequently report feeling isolated.

Ocular Melanoma UK came about to provide both support and a voice for those with this rare cancer. We bring people together across the country and provide UK-specific information.

Ocular melanoma is a rare cancer, and patients are frequently excluded from skin melanoma trials, which leaves research limited and reinforces the need for greater investment and understanding. As treatments progress, we remain committed to reducing the barriers that prevent people from receiving timely and appropriate care.

We are committed to ensuring that every patient has the information, support and treatment they need in a timely manner.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

#### **Our aims and objectives**

Ocular Melanoma UK provides members and others with current information and non-clinical advice and support through various channels.

People tell us they wish they had learnt about us when they were first diagnosed, as they appreciate the information and support we provide. This means a great deal to them, so we have planned several projects to increase our reach so that once someone is diagnosed, they learn about Ocular Melanoma UK, the services we provide, and that we can encourage treatment pathways to be developed to ease the pressures people face.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### ***The main activities undertaken during the year to further the charity's purpose for the public benefit.***

During the year, we supported our community by offering the following services:

##### **To Improve Support**

###### Emotional & Practical Support

Our Head of Support is supporting more people through our helpline and manages our online community support groups. These are open to anyone affected by this cancer. The weekly meetings provide a safe place for people to give and receive support with any difficulties they face.

###### Psychological Support

Continued to provide members with timely & funded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have. This allows patients and loved ones throughout the UK to access up to six funded sessions.

###### Health Information

We maintained our PIF TICK accreditation this year, which means our health information is easily recognised as a trusted source. Our resources are reviewed by clinicians to ensure accuracy and are developed with patients, so the content reflects what people genuinely want and need to know. We continue to extend the written information available to people.

With the launch of our new website, we created a dedicated section for trusted, clear and up-to-date information. It is arranged by stage to help people find what they need without feeling overwhelmed.

###### Community Support

As mentioned above, we run regular online sessions for people to come together to remove isolation and facilitate peer-to-peer support online. We continue to develop our local ambassador programme so that people can meet other members throughout the UK in person.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### To Build Knowledge

##### Conference

We held a two-day conference, which was very well attended by patients and family members. Yet again, we had a record number of people who hadn't attended a conference before, and for some, it was the first time they met others with the same condition, which is a huge help in itself.

We also had many leading experts in their field share their knowledge with us, and ensured these talks were recorded and available after the event, so the latest knowledge could be easily shared.

##### Website

Our new website is in its second phase, with cancer-related information being reviewed, adhering to Pif-Tick quality standards and added to our site. Clinical trials have also been added and updated regularly with the support of our Clinical Advisory Panel.

##### Ocular Melanoma October

In October 2024, we launched Ocular Melanoma October, a month-long campaign to raise awareness about ocular melanoma and provide support to those affected by this rare cancer. The campaign featured educational content, community events, and culminated in the first Ocular Melanoma Day on 10 October, marking the charity's 15th anniversary. It resulted in a fourfold increase in our social media reach and connected individuals nationwide through in-person meetings. This success laid the foundation for an expanded awareness initiative next year, with funding already secured. Ocular Melanoma October will now become an annual tradition to amplify our impact and ensure no one faces ocular melanoma alone.

##### Bulletins

We produce a regular bulletin for our members giving updates on our work, how to access the services we provide, and, importantly, information on how people can share their experience with us or decision-makers to drive improvements.

##### Advocacy

We continued to advocate for patients and their families by making sure their voices shape national conversations on care, research and support. We contributed patient perspectives to research studies, engaged with clinicians and policymakers to highlight the realities of living with ocular melanoma, and ensured families were represented in service design discussions. Through our helpline, psychological support service and community forums, we gathered real-world insight that helped us challenge gaps in care and promote improvements across the pathway.

Our advocacy this year has centered on ensuring people have timely access to effective treatments, as reimbursement processes are harming patients. There is an unmet need in terms of treatment and with Chemosat being proven to be safe and effective, we are campaigning for this to be reviewed by NICE and NHS England, and subsequently funded on the NHS. We have repeatedly raised this and are now involving MPs to support our efforts.

The application to the SMC has not yet been submitted, but we are poised to mirror our campaigning in Scotland when it's appropriate.

##### Rare Community

Ocular Melanoma UK is a member of Cancer52 and Genetic Alliance and regularly attends NHS England Cancer Charity meetings so key messages can be communicated to our community, but also allows us to communicate the needs of people affected by ocular melanoma to decision-makers. Our CEO also works with Melanoma Patient Network for Europe and useMYdata, and sits on various projects to improve the lives of people with this cancer.

We have joined Cancer 52's Working Groups on Access to Medicines, Research and Data, as all of these areas should have a noticeable impact on our community.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### To Drive Research

##### Clinical Advisory Panel

We have continued to work with our clinical advisory panel to gain their thoughts on how to resolve areas that are important to patients and to ensure the information we provide is clinically accurate.

##### Research applications

We supported several research applications that we felt would benefit people and met with organisations interested in learning about the impact of this cancer. At times, it was appropriate for us to lead those conversations, but where companies were interested in talking to patients directly, we reviewed the questions that would be asked and offered our support to the people involved.

##### Data

We have worked to improve the data routinely available to researchers and bodies such as NICE & SMC, and will continue to push for better data collection and sharing of data so that the needs of patients are clearly understood.

Our CEO spoke at Cancer Research UK's Data conference on the impact AI could have on care and how the needs of rare cancer patients should be considered, as we risk widening the survival gap between common and rare cancers.

##### Access to Medicines

We continued to build relationships with pharmaceutical companies that have an interest in this cancer to increase the number of trials available to people and to increase the possibility of effective treatments being made available to people.

We continue to encourage NHS England to allow chemosat to be funded and have supported patients while they appeal to private medical companies to have their decisions overturned.

##### Patient Need

We have expanded our reach so that more organisations understand that the needs of rare cancer patients are not being met with the current focus on improving mortality in the UK. We do this through working with organisations that share common goals and enable us to have a voice at a national level.

All this was achieved with the support of our donors and everyone who fundraised for us. We are incredibly grateful to everyone for their efforts over this challenging year, as it enabled us to continue our work and support people through some very difficult times.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### Structure, governance and management of the charity

##### *The methods used to recruit and appoint new charity trustees.*

##### **Governing Document**

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

##### **Management Committee**

All Trustees gave and continue to give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 8 to the accounts. Trustees serve for up to three years and may be re-elected at the Annual General Meeting. The Board of Directors, together with the CEO, acts as the Management Committee.

##### **Trustee Induction**

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

##### **Organisational Structure**

The Management Committee is responsible for the strategic direction and policy of the charity. The CEO has delegated responsibility from the Board for the overall operation of the charity.

##### **Bankers**

CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ

National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House,  
Bairs Road, Middlesex, EN1 1FD

Shawbrook Bank, Lutea House, Warley Hill Business Park, The Drive, Great  
Warley, Brentwood, Essex CM13 3BE

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### Financial review

##### *The charity's financial position at the end of the year ended 31 March 2025*

The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2025	2024
	£	£
<b>Net income</b>	7,442	(688)
Unrestricted Revenue Funds available for the general purposes of the charity	58,549	41,408
Restricted Revenue Funds	26,908	36,607
<b>Total Restricted Funds</b>	26,908	36,607
<b>Total Funds</b>	85,457	78,015

##### *Financial review of the position at the reporting date, 31 March 2025*

The trustees consider the financial performance by the charity during the year to have been satisfactory.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### *Policies on reserves*

This reserves policy aims to establish guidelines for the appropriate level of reserves that Ocular Melanoma UK should maintain. The reserves policy will help ensure that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks. The reserves policy will also provide transparency and accountability to Ocular Melanoma UK's stakeholders, including donors, volunteers, staff, and beneficiaries.

##### Nature of reserves:

For the purposes of this policy, reserves are defined as funds that are held in excess of the immediate needs of Ocular Melanoma UK. Reserves include both unrestricted and restricted funds.

##### Reserves Guidelines:

1. Target Reserves: Ocular Melanoma UK should maintain a target reserve level equivalent to at least six months of operating expenses. The target reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
2. Minimum Reserves: Ocular Melanoma UK should maintain a minimum level of reserves that is equivalent to three months of operating expenses. The minimum reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
3. Use of Reserves: Reserves should only be used for specific purposes, such as emergencies, unexpected expenses, or to support new initiatives. Reserves should not be used to cover ongoing operational deficits or to fund programs that are not sustainable.
4. Investment of Reserves: Reserves should be invested in a prudent manner that balances safety, liquidity, and yield. The investment strategy should be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
5. Reporting on Reserves: Ocular Melanoma UK will report annually on the status of its reserves in its financial statements. This reserves policy ensures that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks.

The policy provides guidelines for the appropriate level of reserves, the use and investment of reserves, and reporting on reserves. The policy will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.

#### *Availability and adequacy of assets of each of the funds*

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### *Plans For the Future*

##### **Summary of plans for the future and the trustees' perspective of the future direction of the charity.**

We strive to improve the care, treatment and support that people receive.

In the year ahead, we will continue our work so that once someone is diagnosed, they learn about Ocular Melanoma UK and the services we provide, and that treatment pathways evolve to ease the pressures we know people face. We identified several ways to reduce these pressures, strengthening our charity so it can help people and their families through these difficult times.

In addition to the services outlined earlier in this report, we will continue to focus our efforts to:

1. Reduce delays in accessing treatment for metastatic disease and
2. Increase our services that reduce isolation and distress.

We will do this by:

##### **Improve Support**

- Allow patients to book scheduled helpline calls so they can access support at a time that feels manageable for them.
- Build a peer-to-peer network to support nurses and help them guide their patients throughout diagnosis and treatment.
- Continue to develop our suite of patient booklets and tailor this information for our website so people can easily find trusted, relevant information whenever they need it.
- Increase awareness of clinical trials by sharing all known studies on our website, recognising that there is no other single resource bringing these options together for our community.
- Introduce a chatbot on our website to help people quickly find information and support, particularly out of hours.

##### **Build Knowledge**

- Launch a survey to understand the day-to-day impact of ocular melanoma on people and their families, and make the insights widely available to support improvements in care and service design.
- Learn from the EUPATI Patient Expert Training Programme to strengthen our ability to contribute meaningfully to research discussions and ensure patient perspectives remain central to clinical decision making.
- Attend key meetings in the UK and abroad, including speaking at the Use MY Data conference, so the lived experience of ocular melanoma is represented wherever decisions are made.
- Represent our community across national and international forums, including NICE, SMC and NHS reviews, and through our CEO's role with EURACAN as the ePag for eye cancer.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### Drive Research

- Begin a scheme to support early detection of ocular melanoma, recognising that in the absence of a cure, early diagnosis is one of the strongest opportunities to improve survival and quality of life.
- Continue to raise awareness of the disease so people are diagnosed sooner and have better access to timely treatment.
- Share real-world patient insight from our services, helping researchers and clinicians understand the challenges people face and shape studies that truly reflect patient needs.

#### Be Sustainable

- Expand the team to support our fundraisers and enable our Head of Marketing and Fundraising to plan work to support more people, including through initiatives such as Ocular Melanoma October.
- Encourage members to share how our support has helped them, strengthening our community and inspiring others to fundraise or get involved.
- Launch an overseas challenge event in response to member requests, helping diversify income and strengthen community engagement.
- Use all available resources wisely so our small team is positioned where it can have the greatest impact.
- Strengthen internal processes and digital tools, including the introduction of our new chatbot, to ensure we remain efficient, responsive and resilient as we grow.

Everything Ocular Melanoma UK has achieved continues to come from sheer dedication and a passion to make real change in the lives of those affected by this dreadful cancer.

We will continue until we have a world where people with ocular melanoma can live, and live well.

### Details of The Independent Examiner

Tracey Pritchard BA FCA  
Chartered Accountant  
255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

**Ocular Melanoma UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2025**

**Method of preparation of accounts - Small company provisions**

The financial statements are set out on pages 16 to 35.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 18/12/ 2025.



MRS C EDWARDS  
Director and Trustee

## Ocular Melanoma UK

### Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2025

I report to the Trustees on my examination of the financial statements of the charitable company on pages 16 to 35 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 21.

#### Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 12, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

## Ocular Melanoma UK

### Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

This report was signed on 18/12/2025

**Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025**

**Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2025, as required by the Companies Act 2006)**

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2025	2025	2025	2024
		£	£	£	£
<b>Income &amp; Endowments from:</b>					
Donations & Legacies	A1	56,302	69,884	126,186	103,133
Charitable activities	A2	247	-	247	325
Other trading activities	A3	53,531	-	53,531	45,317
Investments	A4	939	-	939	520
<b>Total income</b>	<b>A</b>	<b>111,019</b>	<b>69,884</b>	<b>180,903</b>	<b>149,295</b>
<b>Expenditure on:</b>					
Raising funds	B1	6,777	-	6,777	2,972
Charitable activities	B2	87,101	79,583	166,684	147,011
<b>Total expenditure</b>	<b>B</b>	<b>93,878</b>	<b>79,583</b>	<b>173,461</b>	<b>149,983</b>
<b>Net income for the year</b>		<b>17,141</b>	<b>(9,699)</b>	<b>7,442</b>	<b>(688)</b>
<b>Transfers between funds</b>	<b>C</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income after transfers</b>	<b>A-B-C</b>	<b>17,141</b>	<b>(9,699)</b>	<b>7,442</b>	<b>(688)</b>
<b>Net movement in funds</b>		<b>17,141</b>	<b>(9,699)</b>	<b>7,442</b>	<b>(688)</b>
<b>Reconciliation of funds:-</b>					
<b>Total funds brought forward</b>		<b>41,408</b>	<b>36,607</b>	<b>78,015</b>	<b>78,703</b>
<b>Total funds carried forward</b>		<b>58,549</b>	<b>26,908</b>	<b>85,457</b>	<b>78,015</b>

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

**The notes attached on pages 21 to 35 form an integral part of these accounts.**

Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025

Ocular Melanoma UK - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
<b>Income &amp; Endowments from:</b>				
Donations & Legacies	A1	42,133	61,000	103,133
Charitable activities	A2	325	-	325
Other trading activities	A3	45,317	-	45,317
Investments	A4	520	-	520
<b>Total income</b>	<b>A</b>	<u>88,295</u>	<u>61,000</u>	<u>149,295</u>
<b>Expenditure on:</b>				
Raising funds	B1	2,972	-	2,972
Charitable activities	B2	90,800	56,211	147,011
<b>Total expenditure</b>	<b>B</b>	<u>93,772</u>	<u>56,211</u>	<u>149,983</u>
Net gains on investments	B4	-	-	-
<b>Net income for the year</b>		(5,477)	4,789	(688)
<b>Transfers between funds</b>	<b>C</b>			-
<b>Net income after transfers</b>		<u>(5,477)</u>	<u>4,789</u>	<u>(688)</u>
<b>Net movement in funds</b>		<u>(5,477)</u>	<u>4,789</u>	<u>(688)</u>
<b>Reconciliation of funds:-</b>				
<b>Total funds brought forward</b>		54,910	23,793	78,703
<b>Total funds carried forward</b>		<u>49,433</u>	<u>28,582</u>	<u>78,015</u>

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025

### Ocular Melanoma UK - Resources applied in the year ended 31 March 2025 towards fixed assets for Charity use:-

	2025 £	2024 £
Funds generated in the year as detailed in the SOFA	7,442	(688)
Resources applied on functional fixed assets	-	-
Other applications of funds	-	-
<b>Net resources available to fund charitable activities</b>	<u>7,442</u>	<u>(688)</u>

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 21 to 35 form an integral part of these accounts.

### Movements in revenue and capital funds for the year ended 31 March 2025

#### Revenue accumulated funds

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last year Total Funds 2024 £
Accumulated funds brought forward	41,408	36,607	78,015	78,703
Recognised gains and losses before transfers	17,141	(9,699)	7,442	(688)
	<u>58,549</u>	<u>26,908</u>	<u>85,457</u>	<u>78,015</u>
(From)/To unrestricted revenue funds	-	-	-	-
<b>Closing revenue funds</b>	<u>58,549</u>	<u>26,908</u>	<u>85,457</u>	<u>78,015</u>

#### Summary of funds

	Unrestricted and Designated funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Total Funds 2024 £
Revenue accumulated funds	58,549	26,908	85,457	78,015

The notes attached on pages 21 to 35 form an integral part of these accounts.

**Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025**

**Ocular Melanoma UK  
Income and Expenditure Account for the year ended 31 March 2025 as required by the  
Companies Act 2006**

	2025 £	2024 £
<i>Income</i>		
Income from operations	179,964	148,775
Investment income		
Interest receivable	939	520
<b>Gross income in the year before exceptional items</b>	<b>180,903</b>	<b>149,295</b>
<b>Gross income in the year including exceptional items</b>	<b>180,903</b>	<b>149,295</b>
<i>Expenditure</i>		
Charitable expenditure, excluding depreciation and amortisation	165,318	145,598
Depreciation and amortisation	142	243
Fundraising costs	6,777	2,972
Governance costs	1,224	1,170
<b>Total expenditure in the year</b>	<b>173,461</b>	<b>149,983</b>
<b>Net income before tax in the financial year</b>	<b>7,442</b>	<b>(688)</b>
Tax on surplus on ordinary activities	-	-
<b>Net income after tax in the financial year</b>	<b>7,442</b>	<b>(688)</b>
<b>Retained surplus for the financial year</b>	<b>7,442</b>	<b>(688)</b>

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

**The notes attached on pages 21 to 35 form an integral part of these accounts.**

Ocular Melanoma UK - Balance Sheet as at 31 March 2026

	SORP		2025	2024
	Note	Ref	£	£
<b>Fixed assets</b>				
Tangible assets	10	A2	96	238
<b>Current assets</b>				
Stocks	11	B1	4,386	2,108
Debtors	12	B2	22,884	-
Cash at bank and in hand		B4	59,827	77,273
<b>Total current assets</b>			<u>87,097</u>	<u>79,381</u>
<b>Creditors: amounts falling due within one year</b>	13	C1	<u>(1,736)</u>	<u>(1,604)</u>
<b>Net current assets</b>			85,361	77,777
<b>The total net assets of the charity</b>			<u><b>85,457</b></u>	<u><b>78,015</b></u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

<b>Restricted funds</b>				
Restricted Revenue Funds	17	D2	26,908	36,607
			26,908	36,607
<b>Unrestricted Funds</b>				
Unrestricted Revenue Funds	17	D3	58,549	41,408
			<u>58,549</u>	<u>41,408</u>
<b>Total charity funds</b>			<u><b>85,457</b></u>	<u><b>78,015</b></u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 15.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



**MRS C EDWARDS**

Trustee

Approved by the board of trustees on 18/12/21 2025

The notes attached on pages 21 to 35 form an integral part of these accounts.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 1 Accounting policies

##### *Policies relating to the production of the accounts.*

##### **Basis of preparation and accounting convention**

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

##### **Risks and future assumptions**

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the Ocular Melanoma UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

##### **Accounting for deferred income and income received in advance**

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

#### ***Policies relating to assets, liabilities and provisions and other matters.***

##### ***Tangible fixed assets***

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

##### **Stocks and work in progress**

Stock is valued at the lower of cost and net realisable value.

##### **Fund Accounting**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

#### 3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

#### 4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

#### 5 Net surplus before tax in the financial year

	2025	2024
	£	£
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	142	243
Pension costs	2,429	3,886

#### 6 Staff costs and emoluments

<i>Salary costs</i>	2025	2024
	£	£
Gross Salaries excluding trustees and key management personnel	82,885	97,851
Employer's operating costs of defined contribution pension schemes	2,429	3,886
<b>Total salaries, wages and related costs</b>	<b>85,314</b>	<b>101,737</b>

The average number of full time staff employed in the year was	1	1
The estimated full time equivalent number of all staff employed in the year was	3	3

#### *The estimated equivalent number of full time staff deployed in different activities in the year was:-*

Engaged on charitable activities	3	3
<b><i>The estimated full time equivalent number of all staff employed as above</i></b>	<b>3</b>	<b>3</b>

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

#### 7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 8 Remuneration and payments to Trustees and persons connected with them

	2025	2024
	£	£
<i>Remuneration payable to trustees or connected persons</i>		
No trustees or connected persons received remunerations.	-	-

#### 9 Trustees' expenses

No trustee expenses were incurred, either in the current or prior year.

#### 10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
At 1 April 2024	-	3,552	-	3,552
Additions	-	-	-	-
<b>At 31 March 2025</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
At 1 April 2024	-	3,314	-	3,314
Charge for the year	-	142	-	142
<b>At 31 March 2025</b>	<b>-</b>	<b>3,456</b>	<b>-</b>	<b>3,456</b>
<b>Net book value</b>				
At 31 March 2025	-	96	-	96
At 31 March 2024	-	238	-	238
 <i>Prior Year</i>				
	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
01 April 2023	-	3,552	-	3,552
Additions	-	-	-	-
<b>31 March 2024</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
01 April 2023	-	3,071	-	3,071
Charge for the year	-	243	-	243
<b>31 March 2024</b>	<b>-</b>	<b>3,314</b>	<b>-</b>	<b>3,314</b>
<b>Net book value</b>				
31 March 2024	-	238	-	238
01 April 2023	-	481	-	481

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

<b>11 Stocks &amp; Work in Progress</b>	<b>2025</b>	<b>2024</b>
	£	£
Stocks before write downs	4,386	2,108
	<u>4,386</u>	<u>2,108</u>
<b>12 Debtors</b>	<b>2025</b>	<b>2024</b>
	£	£
Trade debtors	22,884	-
	<u>22,884</u>	<u>-</u>
<b>13 Creditors: amounts falling due within one year</b>	<b>2025</b>	<b>2024</b>
	£	£
Trade creditors	776	644
Accruals	960	960
	<u>1,736</u>	<u>1,604</u>
<b>14 Income and Expenditure account summary</b>	<b>2025</b>	<b>2024</b>
	£	£
At 1 April 2024	78,015	78,703
Surplus after tax for the year	7,442	(688)
At 31 March 2025	<u>85,457</u>	<u>78,015</u>

### 15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

### 16 Particulars of how particular funds are represented by assets and liabilities

<b>At 31 March 2025</b>	<b>Unrestricted funds</b>	<b>Designated funds</b>	<b>Restricted funds</b>	<b>Total Funds</b>
	£	£	£	£
Tangible Fixed Assets	96	-	-	96
Current Assets	60,189	-	26,908	87,097
Current Liabilities	(1,736)	-	-	(1,736)
	<u>58,549</u>	<u>-</u>	<u>26,908</u>	<u>85,457</u>
<b>At 1 April 2024</b>	<b>Unrestricted funds</b>	<b>Designated funds</b>	<b>Restricted funds</b>	<b>Total Funds</b>
	£	£	£	£
Tangible Fixed Assets	238	-	-	238
Current Assets	42,774	-	36,607	79,381
Current Liabilities	(1,604)	-	-	(1,604)
	<u>41,408</u>	<u>-</u>	<u>36,607</u>	<u>78,015</u>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2024	Movement in funds in 2025	Transfers between funds in 2025	Funds carried forward to 2026
	£	See Note 18 £	£	£
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	41,408	17,141	-	58,549
<b>Total unrestricted and designated funds</b>	<b>41,408</b>	<b>17,141</b>	<b>-</b>	<b>58,549</b>
<b>Restricted funds:-</b>				
Annual Conference	7,167	(6,667)	-	500
Patient folder	3,675	-	-	3,675
Patient Information to PifTick standard	1,883	(173)	-	1,710
Resources HCP	2,333	1,768	-	4,101
Trial Database	2,333	125	-	2,458
Helpline Advisor Role and Support	10,544	(6,069)	-	4,475
Psychological Support	4,839	817	-	5,656
Educational Event	3,833	500	-	4,333
<b>Total restricted funds</b>	<b>36,607</b>	<b>(9,699)</b>	<b>-</b>	<b>26,908</b>
<b>Total charity funds</b>	<b>78,015</b>	<b>7,442</b>	<b>-</b>	<b>85,457</b>

#### 18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2025 £	2025 £	2025 £	2025 £
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	111,019	(93,878)	-	17,141
<b>Restricted funds:-</b>				
Conference	24,349	(31,016)	-	(6,667)
Patient folder	-	-	-	-
Patient Information to PifTick standard	16,700	(16,873)	-	(173)
Resources HCP	1,900	(132)	-	1,768
Trial Database	1,900	(1,775)	-	125
Helpline Advisor Role and Support	14,035	(20,104)	-	(6,069)
Psychological Support	10,500	(9,683)	-	817
Educational Event	500	-	-	500
<b>Total</b>	<b>180,903</b>	<b>(173,461)</b>	<b>-</b>	<b>7,442</b>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 19 The purposes for which the funds are

##### *Unrestricted and designated funds:-*

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

##### *Restricted funds:-*

Restricted Revenue Funds:

Restricted funds are funds that donors have given for a particular purpose and/or project as outlined by donors and may include other connected costs. The aim and use of each restricted fund are detailed in the notes of the financial statements.

#### 20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

*This analysis is classified by conventional nominal descriptions and not by activity.*

### 21 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Small donations individually less than £1000	30,057	-	30,057	21,996
anonymous donors	2,943	-	2,943	2,329
CLS UK	-	-	-	1,000
In Memory	10,802	-	10,802	13,786
<b>Total donations and gifts from individuals</b>	<b>43,802</b>	<b>-</b>	<b>43,802</b>	<b>39,111</b>

#### Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Prior year	39,111	-	39,111

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Legacies receivable				
IM JH	10,000	-	10,000	-
<b>Total legacies receivable</b>	<b>10,000</b>	<b>-</b>	<b>10,000</b>	<b>-</b>

#### Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Prior year	-	-	-

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### Revenue grants and donations from non public bodies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Delcath Systems Ltd	-	15,000	15,000	11,000
Immunocore Limited	-	32,000	32,000	32,000
Aura Biosciences	-	22,884	22,884	-
Vision Foundation	-	-	-	9,000
Alan Boswell Charity ALA	-	-	-	3,022
Souter Charitable Trust	-	-	-	3,000
TriSalus Life Science	-	-	-	3,000
Ideaya Biosciences	2,500	-	2,500	3,000
<b>Total private sector revenue grants</b>	<b>2,500</b>	<b>69,884</b>	<b>72,384</b>	<b>64,022</b>

### Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
<b>Prior Year</b>	<b>3,022</b>	<b>61,000</b>	<b>64,022</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### Total Donations, Grants and Legacies

		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
<i>Current year</i>		2025	2025	2025	2024
		£	£	£	£
<b>Total Donations, Grants and Legacies</b>	A1	<b>56,302</b>	<b>69,884</b>	<b>126,186</b>	<b>103,133</b>
<i>Prior year</i>		Unrestricted Funds 2024	Restricted Funds 2024	Prior Year Total Funds 2024	
		£	£	£	
<b>Total Donations, Grants and Legacies</b>	A1	<b>42,133</b>	<b>61,000</b>	<b>103,133</b>	

### 22 Income from charitable activities - Trading Activities

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
<i>Current year</i>		2025	2025	2025	2024
		£	£	£	£
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		247	-	247	325
<b>Total Primary purpose and ancillary trading</b>		<b>247</b>	<b>-</b>	<b>247</b>	<b>325</b>
<i>Prior year</i>		Prior Year Unrestricted Funds 2024	Prior Year Restricted Funds 2024	Prior Year Total Funds 2024	
		£	£	£	
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		325	-	325	
<b>Total Primary purpose and ancillary trading</b>		<b>325</b>	<b>-</b>	<b>325</b>	

## Ocular Melanoma UK

### Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

#### 23 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Total income from charitable trading	247	-	247	325
<b>Total from charitable activities</b> <b>A2</b>	<b>247</b>	<b>-</b>	<b>247</b>	<b>325</b>

#### Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Total income from charitable trading	325	-	325
	<b>325</b>	<b>-</b>	<b>325</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Income from fundraising events	53,531	-	53,531	45,317
<b>Total from other activities</b>	<b>53,531</b>	<b>-</b>	<b>53,531</b>	<b>45,317</b>

### Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	45,317	-	45,317

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 25 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Gross wages and salaries - charitable activities	59,777	23,108	82,885	97,851
Defined contribution pension costs - charitable activities	2,429	-	2,429	3,886
Travel and Subsistence - Charitable Activities	2,828	-	2,828	747
Marketing and advertising of charitable services	3,918	1,332	5,250	118
Charitable activities costs	2,253	52,475	54,728	26,706
Staff welfare	261	-	261	-
<b>Total direct spending</b>	<b>71,466</b>	<b>76,915</b>	<b>148,381</b>	<b>129,308</b>

All the expenditure in the prior year was unrestricted.

<i>Prior Year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Gross wages and salaries - charitable activities	66,951	30,900	97,851
Defined contribution pension costs - charitable activities	3,886	-	3,886
Travel and Subsistence - Charitable Activities	747	-	747
Marketing and advertising of charitable services	118	-	118
Charitable activities costs	1,395	25,311	26,706
<b>Total direct spending</b>	<b>73,097</b>	<b>56,211</b>	<b>129,308</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 26 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
<b><i>Employee costs not included in direct costs</i></b>				
Recruitment expenses	-	-	-	256
<b><i>Administrative overheads</i></b>				
Telephone, fax and internet	161	1,788	1,949	1,885
Stationery and printing	257	-	257	597
Membership subscriptions	2,959	-	2,959	2,662
Software licences and expenses	5,308	-	5,308	2,682
Sundry expenses	32	-	32	-
Insurance	1,019	-	1,019	907
<b><i>Professional fees paid to advisors other than the auditor or examiner</i></b>				
Accountancy fees other than examination or audit fees	952	880	1,832	1,772
Other legal and professional	3,484	-	3,484	5,363
<b><i>Financial costs</i></b>				
Bank charges	97	-	97	132
Depreciation & Amortisation in total for the period	142	-	142	243
<b>Support costs before reallocation</b>	<b>14,411</b>	<b>2,668</b>	<b>17,079</b>	<b>16,499</b>
<b>Total support costs - Current Year</b>	<b>14,411</b>	<b>2,668</b>	<b>17,079</b>	<b>16,499</b>

The basis of allocation of costs between activities is described under accounting policies  
All the expenditure in the prior year was unrestricted.

### 27 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Independent Examiner's fees	1,224	-	1,224	1,170
<b>Total Governance costs</b>	<b>1,224</b>	<b>-</b>	<b>1,224</b>	<b>1,170</b>

All the expenditure in the prior year was unrestricted.

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 28 Total Charitable expenditure

		Current year	Current year	Current year	Prior Year
		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
<i>Current Year</i>		2025	2025	2025	2024
		£	£	£	£
Total direct spending	<b>B2a</b>	71,466	76,915	148,381	129,308
Total charitable trading costs	<b>B2b</b>	-	-	-	34
Total support costs	<b>B2d</b>	14,411	2,668	17,079	16,499
Total Governance costs	<b>B2e</b>	1,224	-	1,224	1,170
<b>Total charitable expenditure</b>	<b>B2</b>	<b>87,101</b>	<b>79,583</b>	<b>166,684</b>	<b>147,011</b>
<i>Prior Year</i>		Prior Year	Prior Year	Prior Year	
		Unrestricted Funds	Restricted Funds	Total Funds	
		2024	2024	2024	
		£	£	£	
Total direct spending	<b>B2a</b>	73,097	56,211	129,308	
Total charitable trading costs	<b>B2b</b>	34	-	34	
Total support costs	<b>B2d</b>	16,499	-	16,499	
Total Governance costs	<b>B2e</b>	1,170	-	1,170	
<b>Total charitable expenditure</b>	<b>B2</b>	<b>90,800</b>	<b>56,211</b>	<b>147,011</b>	

### 29 Expenditure on raising funds and costs of investment management

		Current year	Current year	Current year	Prior Year
		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
<i>Current Year</i>		2025	2025	2025	2024
		£	£	£	£
Cost of fundraising activities		6,777	-	6,777	2,972
<b>Total fundraising costs</b>	<b>B1</b>	<b>6,777</b>	<b>-</b>	<b>6,777</b>	<b>2,972</b>

All the expenditure in the prior year was unrestricted.

**Ocular Melanoma UK**

England & Wales - Charity number 1147506

---

# Accounts

---

Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

Ocular Melanoma UK

Report and Accounts

31 March 2024

**Ocular Melanoma UK**

**Report and accounts for the year ended 31 March 2024**

**Contents**

	<b>Page</b>
<b>Charity information</b>	1
<b>Trustees' Annual Report</b>	1
<b>Statement of directors' responsibilities</b>	11
<b>Independent Accountant's Report</b>	13
<b><i>Funds Statements:-</i></b>	
Statement of Financial Activities	15
Statement of Financial Activities - Prior Year statement	16
Movements in funds	17
Income and Expenditure account	18
<b>Balance sheet</b>	19
<b>Notes to the accounts</b>	20

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2024**

The Trustees present their Report and Accounts for the year ended 31 March 2024, which also comprises the Directors' Report required by the Companies Act 2006.

#### **Reference and administrative details**

##### ***The charity name.***

The legal name of the charity is:- Ocular Melanoma UK.

The charity is also known by its operating name, Ocular Melanoma UK.

##### ***The charity's areas operation and UK charitable registration.***

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

##### ***Legal structure of the charity***

The charity is constituted as a company limited by guarantee, registered under the Companies Acts .

The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

Updated Articles of Association and Special Resolution are dated 20th August 2024

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

##### **The principal operating address, telephone number, email and web addresses of the charity are:-**

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address [info@omuk.org](mailto:info@omuk.org)

Web Address [www.omuk.org](http://www.omuk.org)

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### The Trustees in office on the date the report was approved were:-

Mr Neil Pearce

Mrs Alison Benjamin

Mrs Joanne Morgan - Chair

Mr Gianfranco De Franco

Mr Colin White

Mrs Charlotte Edwards - Treasurer

#### The following persons served as Trustees during the year ended 31 March 2024 :-

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-.

<b>Name</b>	<b>Appointed</b>	<b>Resigned/Retired</b>
Mr Neil Pearce		
Mrs Alison Benjamin		
Mrs Joanne Morgan - Chair		
Mr Gianfranco De Franco		
Mr Colin White		
Mrs Charlotte Edwards - Treasurer		

All the trustees are also members of the charity.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### Objects and activities of the charity

##### ***The purposes of the charity.***

Ocular Melanoma UK is the only UK charity solely dedicated to supporting people affected by ocular melanoma. We have been helping people since 2011 with this rare cancer so they could talk to others about their cancer diagnosis and adjust to life if they experience vision loss.

We are determined to drive improvements so people can live well with ocular melanoma. This can be a devastating cancer so we are working to ensure people have access to effective treatments and that clear pathways are in place, all while striving to provide specialist support to people who need it.

##### **What is ocular melanoma?**

Ocular melanoma is a cancer of the eye.

- We know approximately 750 people in the UK will hear they have ocular melanoma each year and those people are likely to need support.
- We know we have hundreds of people in the UK living with ocular melanoma who may need support adjusting to life after their diagnosis.
- We also know one in every two people will hear they need further treatment if the cancer spreads
- We know that no one should face this terrifying time alone.

Ocular melanoma includes two cancers, uveal and conjunctival melanoma. Uveal melanoma includes the iris, choroid or ciliary body. Both types of ocular melanoma can metastasise (spread) to other organs, with the liver typically involved in 90% of uveal melanoma cases.

If ocular melanoma spreads to another organ, it is currently incurable. Some treatments extend life expectancy and improve the quality of life for some patients, but patients can face difficulties accessing these treatments.

Ocular melanoma is usually discovered during a routine eye examination, or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects cancer, they should urgently refer the patient to their local ophthalmology department, should they agree with the concern, they will refer to one of four specialist centres: Glasgow, Liverpool, Sheffield or London.

##### **Why is Ocular Melanoma UK needed?**

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming, that patients frequently report feeling isolated. Ocular Melanoma UK came about to provide both support and a voice for those with this rare cancer. We bring people together across the country and provide UK-specific information.

Ocular Melanoma patients are often excluded from skin melanoma trials, so research is limited. Treatments are progressing, but many people face barriers to receiving treatments

Ocular Melanoma UK is raising the disease profile within the medical community and decision-makers. We work to improve patients' access to effective treatments, and eventually financially support research.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### Our aims and objectives

Our Vision is a world where people with ocular melanoma can live, and live well.

Our Mission is to advocate for change by uniting people against ocular melanoma cancers so that every person receives the treatment, information and support they need.

Ocular Melanoma UK's charitable objectives are:

1. To primarily promote and protect the physical and mental health of people with ocular melanoma and their families in the United Kingdom through support, information, education and practical advice.
2. To support research into ocular melanoma and to publish the useful results.

#### ***The main activities undertaken during the year to further the charity's purpose for the public benefit.***

Ocular Melanoma UK provides members and others with current information and non-clinical advice and support through various channels.

People tell us they wish they learnt about us when they were first diagnosed as they appreciate the information and support we provide. This means a great deal to them, so we have planned several projects to increase our reach so that once someone is diagnosed, they learn about Ocular Melanoma UK, the services we provide, and that we can encourage treatment pathways to be developed to ease the pressures people face.

During the year, we supported our community by offering the following services:

#### **To Improve Support**

##### Emotional & Practical Support

We recruited a dedicated Helpline Advisor who is supporting more people through our helpline and manages our online community support groups which are open to anyone affected by this cancer. These weekly meetings provide a safe place for people to give and receive support with any difficulties they face.

##### Psychological Support

Continued to provide members with timely & funded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have. This allows patients and loved ones throughout the UK to access up to six funded sessions.

##### Health Information

We gained pif-tick accreditation so our health information is easily recognised as a trusted source of information and reviewed by clinicians to ensure it is clinically accurate and written in conjunction with patients so it contains information that they would find useful.

Our first booklet is now available on our website for people with metastatic disease and we will be launching the next booklets about the condition and receiving treatment for the primary tumour shortly.

##### Community Support

As mentioned above, we run regular online sessions for people to come together to remove isolation and facilitate peer-to-peer support. We have also increased the number of local ambassadors so that people can meet other members throughout the UK in person.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### To Build Knowledge

##### Conference

We held a two-day conference which was very well attended by patients and family members. We had a record number of people who hadn't attended a conference before and for some, it was the first time they met others with the same condition, which is a huge help in itself.

We also had some of the leading experts in their field share their knowledge with us. Every year, we ensure these talks are recorded and available after the event so the latest knowledge is easily shared.

##### Website

We have launched a new website which now meets accessibility criteria, [www.omuk.org](http://www.omuk.org). We have launched this in phases so that all cancer-related information adheres to pif-tick quality health information standards and have now begun work on building a resource for people to find details of the clinical trials they could be eligible for and we are building an area for clinicians to find information easily.

##### Ocular Melanoma October

In October 2024, we launched Ocular Melanoma October, a month-long campaign to raise awareness about ocular melanoma and provide support to those affected by this rare cancer. The campaign featured educational content, community events, and culminated in the first Ocular Melanoma Day on 10 October, marking the charity's 15th anniversary. It resulted in a fourfold increase in our social media reach and connected individuals nationwide through in-person meetings. This success laid the foundation for an expanded awareness initiative next year, with funding already secured. Ocular Melanoma October will now become an annual tradition to amplify our impact and ensure no one faces ocular melanoma alone.

##### Bulletins

We produce a regular bulletin for our members giving updates on our work, how to access the services we provide, and importantly, information on how people can share their experience with us or decision-makers to drive improvements.

##### Advocacy

This has been a large part of our work as NICE felt a new drug should not be made available. We successfully appealed this decision and it was recently announced that this new treatment, Tebentafusp will be available to people on the NHS. We continued to involve our community at every stage by running focus groups and we worked closely with two patients so they could attend the meetings and explain to the committee what it was like to live with this condition. One of our members shared her experience of taking the new drug through the clinical trial and this insight was incredibly useful for the committee.

##### Rare Community

Ocular Melanoma UK is a member of Cancer52 and Genetic Alliance and regularly attends NHS England Cancer Charity meetings so key messages can be communicated to our community, but also allows us to communicate the needs of people affected by ocular melanoma to decision-makers. Our CEO also works with Melanoma Patient Network for Europe and useMYdata and sits on various projects to improve the lives of people with this cancer.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### To Drive Research

##### Clinical Advisory Panel

We have continued to work with our clinical advisory panel to gain their thoughts on how to resolve areas that are important to patients and to ensure the information we provide is clinically accurate.

##### Research applications

We supported several research applications that we felt would benefit people and met with organisations interested in learning about the impact of this cancer. At times it was appropriate for us to lead those conversations, but where companies were interested in talking to patients directly, we reviewed the questions that would be asked and offered our support to the people involved.

##### Data

We have worked to improve the data routinely available to researchers and bodies such as NICE & SMC and will continue to push for better data collection and sharing of data so that the needs of patients are clearly understood.

##### Access to Medicines

We continued to build relationships with pharmaceutical companies who have an interest in this cancer to increase the number of trials available to people and to increase the possibility of effective treatments being made available to people.

We successfully appealed a decision by NICE to not recommend a new drug and are very pleased that patients can now receive this treatment on the NHS.

We continue to encourage NHS England to allow chemosat to be funded and have supported patients while they appeal to private medical companies to have their decisions overturned.

##### Patient Need

We have expanded our reach so that more organisations understand that the needs of rare cancer patients are not being met with the current focus on improving mortality in the UK. We do this through working with organisations that share common goals and enable us to have a voice at a national level.

All this was achieved with the support of our donors and everyone who fundraised for us. We are incredibly grateful to everyone for their efforts over this challenging year as it enabled us to continue our work and support people through some very difficult times.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2024**

#### **Structure, governance and management of the charity**

##### ***The methods used to recruit and appoint new charity trustees.***

##### **Governing Document**

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

##### **Management Committee**

Our CEO was a trustee of the charity up until 31/03/23 and this was approved by the Charity Commission. All other Trustees gave and continue to give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 8 to the accounts. Trustees serve for up to three years and may be re-elected at the Annual General Meeting. The Board of Directors, together with the CEO, acts as the Management Committee.

##### **Trustee Induction**

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

##### **Organisational Structure**

The Management Committee is responsible for the strategic direction and policy of the charity. The CEO has delegated responsibility from the Board for the overall operation of the charity.

Bankers	CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House, Bairs Road, Middlesex, EN1 1FD Shawbrook Bank, Lutea House, Warley Hill Business Park, The Drive, Great Warley, Brentwood, Essex CM13 3BE
---------	---

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### Financial review

#### *The charity's financial position at the end of the year ended 31 March 2024*

The financial position of the charity at 31 March 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2024	2023
	£	£
<b>Net income</b>	(688)	(11,805)
Unrestricted Revenue Funds available for the general purposes of the charity	41,408	54,910
Restricted Revenue Funds	36,607	23,793
<b>Total Restricted Funds</b>	36,607	23,793
<b>Total Funds</b>	78,015	78,703

#### *Financial review of the position at the reporting date, 31 March 2024*

The trustees consider the financial performance by the charity during the year to have been satisfactory.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2024**

#### ***Policies on reserves***

This reserves policy aims to establish guidelines for the appropriate level of reserves that Ocular Melanoma UK should maintain. The reserves policy will help ensure that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks. The reserves policy will also provide transparency and accountability to Ocular Melanoma UK's stakeholders, including donors, volunteers, staff, and beneficiaries.

##### **Nature of reserves:**

For the purposes of this policy, reserves are defined as funds that are held in excess of the immediate needs of Ocular Melanoma UK. Reserves include both unrestricted and restricted funds.

##### **Reserves Guidelines:**

1. **Target Reserves:** Ocular Melanoma UK should maintain a target reserve level equivalent to at least six months of operating expenses. The target reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
2. **Minimum Reserves:** Ocular Melanoma UK should maintain a minimum level of reserves that is equivalent to three months of operating expenses. The minimum reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
3. **Use of Reserves:** Reserves should only be used for specific purposes, such as emergencies, unexpected expenses, or to support new initiatives. Reserves should not be used to cover ongoing operational deficits or to fund programs that are not sustainable.
4. **Investment of Reserves:** Reserves should be invested in a prudent manner that balances safety, liquidity, and yield. The investment strategy should be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
5. **Reporting on Reserves:** Ocular Melanoma UK will report annually on the status of its reserves in its financial statements. This reserves policy ensures that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks.

The policy provides guidelines for the appropriate level of reserves, the use and investment of reserves, and reporting on reserves. The policy will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.

#### ***Availability and adequacy of assets of each of the funds***

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2024**

#### ***Plans For the Future***

##### **Summary of plans for the future and the trustees' perspective of the future direction of the charity.**

We strive to improve the care, treatment and support patients receive.

We will continue our work so that once someone is diagnosed, they learn about Ocular Melanoma UK & the services we provide, and that treatment pathways are developed to ease the pressures that we know people face.

We identified several ways to reduce these pressures, building our small charity so it can help people and their families through these difficult times.

In addition to the services outlined earlier in this report, we will continue to focus efforts to

Reduce delays in accessing treatment for metastatic disease and  
Increase our services that reduce isolation and distress.

We will do this by

- Ensuring people can easily find clinical trials known to us as these will be shared on the new website. This remains incredibly important as there is no other resource that shows all the trials that could be useful to our patients.
- Representing our community at NICE, SMC & NHS reviews so that treatments that can help our community become available to the patients that need them.
- Continuing the development of a suite of literature with information that our community feels is important, and ensuring we continue to meet pif-tick standards so we are a trusted source of health information.
- Raising the profile of this disease so that people are diagnosed sooner and this cancer has a lesser impact on them.
- Hosting a conference for people to learn more about clinical developments in this area, information on how people can live well with this cancer, and importantly to bring people together for peer-to-peer support.
- Increasing the number of volunteers, including our local ambassadors so local meetings can take place around the country.
- Using all the resources we have available so that we are not held back because of financial constraints. Our support is important to people, so we will ensure our small team is correctly placed to achieve the plans outlined in our 3-year strategy.

Everything Ocular Melanoma UK has achieved has been through sheer dedication and a passion to make a real change in the lives of those affected by this dreadful cancer.

We will continue until we have a world where people with ocular melanoma can live, and live well.

#### **Details of The Independent Examiner**

Tracey Pritchard BA FCA  
Member of Chartered Accountant  
255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2024

#### Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

**Ocular Melanoma UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2024**


**Method of preparation of accounts - Small company provisions**

The financial statements are set out on pages 15 to 34.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 17 December 2024.



**MRS C EDWARDS**  
Director and Trustee

## Ocular Melanoma UK

### Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2024

I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 34 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 20.

#### Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

## Ocular Melanoma UK

### Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;


the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

This report was signed on 17/12/2024

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

### Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2024, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
<b>Income &amp; Endowments from:</b>					
Donations & Legacies	A1	42,133	61,000	103,133	100,037
Charitable activities	A2	325	-	325	141
Other trading activities	A3	45,317	-	45,317	28,754
Investments	A4	520	-	520	238
<b>Total income</b>	<b>A</b>	<b>88,295</b>	<b>61,000</b>	<b>149,295</b>	<b>129,170</b>
<b>Expenditure on:</b>					
Raising funds	B1	2,972	-	2,972	1,144
Charitable activities	B2	90,800	56,211	147,011	139,831
<b>Total expenditure</b>	<b>B</b>	<b>93,772</b>	<b>56,211</b>	<b>149,983</b>	<b>140,975</b>
<b>Net income for the year</b>		<b>(5,477)</b>	<b>4,789</b>	<b>(688)</b>	<b>(11,805)</b>
<b>Transfers between funds</b>	<b>C</b>	<b>(8,025)</b>	<b>8,025</b>	<b>-</b>	<b>-</b>
<b>Net income after transfers</b>	<b>A-B-C</b>	<b>(13,502)</b>	<b>12,814</b>	<b>(688)</b>	<b>(11,805)</b>
<b>Net movement in funds</b>		<b>(13,502)</b>	<b>12,814</b>	<b>(688)</b>	<b>(11,805)</b>
<b>Reconciliation of funds:-</b>					
<b>Total funds brought forward</b>		<b>54,910</b>	<b>23,793</b>	<b>78,703</b>	<b>90,508</b>
<b>Total funds carried forward</b>		<b>41,408</b>	<b>36,607</b>	<b>78,015</b>	<b>78,703</b>

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

**The notes attached on pages 20 to 34 form an integral part of these accounts.**

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

### Ocular Melanoma UK - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
<b>Income &amp; Endowments from:</b>				
Donations & Legacies	A1	34,837	65,200	100,037
Charitable activities	A2	141	-	141
Other trading activities	A3	28,754	-	28,754
Investments	A4	238	-	238
<b>Total income</b>	<b>A</b>	<b>63,970</b>	<b>65,200</b>	<b>129,170</b>
<b>Expenditure on:</b>				
Raising funds	B1	1,144	-	1,144
Charitable activities	B2	98,424	41,407	139,831
<b>Total expenditure</b>	<b>B</b>	<b>99,568</b>	<b>41,407</b>	<b>140,975</b>
Net gains on investments	B4	-	-	-
<b>Net income for the year</b>		<b>(35,598)</b>	<b>23,793</b>	<b>(11,805)</b>
<b>Transfers between funds</b>	<b>C</b>			<b>-</b>
<b>Net income after transfers</b>		<b>(35,598)</b>	<b>23,793</b>	<b>(11,805)</b>
<b>Net movement in funds</b>		<b>(35,598)</b>	<b>23,793</b>	<b>(11,805)</b>
<b>Reconciliation of funds:-</b>				
<b>Total funds brought forward</b>		<b>90,508</b>	<b>-</b>	<b>90,508</b>
<b>Total funds carried forward</b>		<b>54,910</b>	<b>23,793</b>	<b>78,703</b>

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024

### Ocular Melanoma UK - Resources applied in the year ended 31 March 2024 towards fixed assets for Charity use:-

	2024 £	2023 £
Funds generated in the year as detailed in the SOFA	(688)	(11,805)
Resources applied on functional fixed assets	-	(427)
Other applications of funds	-	-
<b>Net resources available to fund charitable activities</b>	<b><u>(688)</u></b>	<b><u>(12,232)</u></b>

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 20 to 34 form an integral part of these accounts.

### Movements in revenue and capital funds for the year ended 31 March 2024

#### Revenue accumulated funds

	Unrestricted Funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £	Last year Total Funds 2023 £
Accumulated funds brought forward	54,910	23,793	78,703	90,508
Recognised gains and losses before transfers	<u>(5,477)</u>	<u>4,789</u>	<u>(688)</u>	<u>(11,805)</u>
	<b>49,433</b>	<b>28,582</b>	<b>78,015</b>	<b>78,703</b>
(From)/To unrestricted revenue funds	(8,025)	8,025	-	-
<b>Closing revenue funds</b>	<b><u>41,408</u></b>	<b><u>36,607</u></b>	<b><u>78,015</u></b>	<b><u>78,703</u></b>

#### Summary of funds

	Unrestricted and Designated funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £	Last Year Total Funds 2023 £
Revenue accumulated funds	41,408	36,607	78,015	78,703

The notes attached on pages 20 to 34 form an integral part of these accounts.

**Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2024**

**Ocular Melanoma UK  
Income and Expenditure Account for the year ended 31 March 2024 as required by the  
Companies Act 2006**

	2024	2023
	£	£
<b>Income</b>		
Income from operations	148,775	128,932
Investment income		
Interest receivable	520	238
<b>Gross income in the year before exceptional items</b>	<b>149,295</b>	<b>129,170</b>
<b>Gross income in the year including exceptional items</b>	<b>149,295</b>	<b>129,170</b>
<b>Expenditure</b>		
Charitable expenditure, excluding depreciation and amortisation	145,598	108,514
Depreciation and amortisation	243	529
Fundraising costs	2,972	1,144
Governance costs	1,170	30,788
<b>Total expenditure in the year</b>	<b>149,983</b>	<b>140,975</b>
<b>Net income before tax in the financial year</b>	<b>(688)</b>	<b>(11,805)</b>
Tax on surplus on ordinary activities	-	-
<b>Net income after tax in the financial year</b>	<b>(688)</b>	<b>(11,805)</b>
<b>Retained surplus for the financial year</b>	<b>(688)</b>	<b>(11,805)</b>

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

**The notes attached on pages 20 to 34 form an integral part of these accounts.**

Ocular Melanoma UK - Balance Sheet as at 31 March 2024

	SORP		2024	2023
	Note	Ref	£	£
<b>Fixed assets</b>	A			
Tangible assets	10	A2	238	481
<b>Current assets</b>	B			
Stocks		B1	2,108	2,108
Debtors	12	B2	-	-
Cash at bank and in hand		B4	77,273	77,236
<b>Total current assets</b>			<u>79,381</u>	<u>79,344</u>
<b>Creditors: amounts falling due within one year</b>	13	C1	<u>(1,604)</u>	<u>(1,122)</u>
<b>Net current assets</b>			77,777	78,222
<b>The total net assets of the charity</b>			<u>78,015</u>	<u>78,703</u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

<b>Restricted funds</b>				
Restricted Revenue Funds	17	D2	36,607	23,793
			36,607	23,793
<b>Unrestricted Funds</b>				
Unrestricted Revenue Funds	17	D3	41,408	54,910
			<u>41,408</u>	<u>54,910</u>
<b>Total charity funds</b>			<u>78,015</u>	<u>78,703</u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



MRS C EDWARDS

Trustee

Approved by the board of trustees on 17 December 2024

The notes attached on pages 20 to 34 form an integral part of these accounts.

# Ocular Melanoma UK

## Notes to the Accounts for the year ended 31 March 2024

### 1 Accounting policies

#### *Policies relating to the production of the accounts.*

##### **Basis of preparation and accounting convention**

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

##### **Risks and future assumptions**

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the Ocular Melanoma UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

##### **Accounting for deferred income and income received in advance**

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2024

#### Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

#### ***Policies relating to assets, liabilities and provisions and other matters.***

##### ***Tangible fixed assets***

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

##### **Stocks and work in progress**

Stock is valued at the lower of cost and net realisable value.

##### **Fund Accounting**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2024

#### 2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

#### 3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

#### 4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

#### 5 Net surplus before tax in the financial year

	2024	2023
	£	£
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	243	529
Trustees' Remuneration as detailed in note 8	-	29,708
Pension costs	3,886	4,195
	<u>3,886</u>	<u>4,195</u>

#### 6 Staff costs and emoluments

<i>Salary costs</i>	2024	2023
	£	£
Gross Salaries excluding trustees and key management personnel	97,851	66,373
Employer's operating costs of defined contribution pension schemes	3,886	4,195
Trustees' Remuneration as detailed in note 8	-	29,708
<b>Total salaries, wages and related costs</b>	<u><b>101,737</b></u>	<u><b>100,276</b></u>

The average number of full time staff employed in the year was	1	1
The estimated full time equivalent number of all staff employed in the year was	3	3

#### *The estimated equivalent number of full time staff deployed in different activities in the year was:-*

Engaged on charitable activities	3	3
<b><i>The estimated full time equivalent number of all staff employed as above</i></b>	<u><b>3</b></u>	<u><b>3</b></u>

The details of remuneration paid to trustees is shown in note 8

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

#### 7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2024

#### 8 Remuneration and payments to Trustees and persons connected with them

	2024	2023
	£	£
<i>Remuneration payable to trustees or connected persons</i>		
Trustee 1	-	28,293
<b>Total remuneration</b>	<b>-</b>	<b>29,708</b>

More detailed information in the Management Committee section on page 7.

#### 9 Trustees' expenses

No trustee expenses were incurred, either in the current or prior year.

#### 10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
At 1 April 2023	-	3,552	-	3,552
Additions	-	-	-	-
<b>At 31 March 2024</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
At 1 April 2023	-	3,071	-	3,071
Charge for the year	-	243	-	243
<b>At 31 March 2024</b>	<b>-</b>	<b>3,314</b>	<b>-</b>	<b>3,314</b>
<b>Net book value</b>				
At 31 March 2024	-	238	-	238
At 31 March 2023	-	481	-	481
 <i>Prior Year</i>				
	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
01 April 2022	-	3,125	-	3,125
Additions	-	427	-	427
<b>01 April 2023</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
01 April 2022	-	2,542	-	2,542
Charge for the year	-	529	-	529
<b>01 April 2023</b>	<b>-</b>	<b>3,071</b>	<b>-</b>	<b>3,071</b>
<b>Net book value</b>				
01 April 2023	-	481	-	481
01 April 2022	-	583	-	583

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2024

<b>11 Stocks &amp; Work in Progress</b>	<b>2024</b>	<b>2023</b>
	£	£
Stocks before write downs	2,108	2,108
	<u>2,108</u>	<u>2,108</u>
<b>12 Debtors</b>	<b>2024</b>	<b>2023</b>
	£	£
Prepayments and accrued income	-	-
<b>13 Creditors: amounts falling due within one year</b>	<b>2024</b>	<b>2023</b>
	£	£
Trade creditors	644	162
Accruals	960	960
	<u>1,604</u>	<u>1,122</u>
<b>14 Income and Expenditure account summary</b>	<b>2024</b>	<b>2023</b>
	£	£
At 1 April 2023	78,703	90,508
Surplus after tax for the year	(688)	(11,805)
At 31 March 2024	<u>78,015</u>	<u>78,703</u>

### 15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

### 16 Particulars of how particular funds are represented by assets and liabilities

<b>At 31 March 2024</b>	<b>Unrestricted</b>	<b>Designated</b>	<b>Restricted</b>	<b>Total</b>
	<b>funds</b>	<b>funds</b>	<b>funds</b>	<b>Funds</b>
	£	£	£	£
Tangible Fixed Assets	238	-	-	238
Current Assets	42,774	-	36,607	79,381
Current Liabilities	(1,604)	-	-	(1,604)
	<u>41,408</u>	<u>-</u>	<u>36,607</u>	<u>78,015</u>
<b>At 1 April 2023</b>	<b>Unrestricted</b>	<b>Designated</b>	<b>Restricted</b>	<b>Total</b>
	<b>funds</b>	<b>funds</b>	<b>funds</b>	<b>Funds</b>
	£	£	£	£
Tangible Fixed Assets	481	-	-	481
Current Assets	55,551	-	23,793	79,344
Current Liabilities	(1,122)	-	-	(1,122)
	<u>54,910</u>	<u>-</u>	<u>23,793</u>	<u>78,703</u>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2024

#### 17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2023	Movement in funds in 2024	Transfers between funds in 2024	Funds carried forward to 2025
	£	See Note 18 £	£	£
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	54,910	(5,477)	(8,025)	41,408
<b>Total unrestricted and designated funds</b>	<b>54,910</b>	<b>(5,477)</b>	<b>(8,025)</b>	<b>41,408</b>
<b>Restricted funds:-</b>				
Patient Education & Events(Annual Conference)	-	7,167	-	7,167
Patient folder	3,675	-	-	3,675
Patient Information to PifTick standard	9,766	(7,883)	-	1,883
Resources HCP	-	2,333	-	2,333
Trial Database	-	2,333	-	2,333
Helpline Advisor Role and Support	7,707	(2,296)	5,133	10,544
Pyschological Support	2,645	(698)	2,892	4,839
Educational Event	-	3,833	-	3,833
<b>Total restricted funds</b>	<b>23,793</b>	<b>4,789</b>	<b>8,025</b>	<b>36,607</b>
<b>Total charity funds</b>	<b>78,703</b>	<b>(688)</b>	<b>-</b>	<b>78,015</b>

#### 18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2024 £	2024 £	2024 £	2024 £
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	88,295	(93,772)	-	(5,477)
<b>Restricted funds:-</b>				
Restricted Fixed Asset Funds	-	-	-	-
Restricted Revaluation Reserve	-	-	-	-
Conference and educational events	21,000	(13,833)	-	7,167
Patient folder	-	-	-	-
Patient Information to PifTick standard	7,833	(15,716)	-	(7,883)
Resources HCP	2,333	-	-	2,333
Trial Database	2,333	-	-	2,333
Helpline Advisor Role and Support	15,333	(17,629)	-	(2,296)
Pyschological Support	8,335	(9,033)	-	(698)
Educational Event	3,833	-	-	3,833
	<b>149,295</b>	<b>(149,983)</b>	<b>-</b>	<b>(688)</b>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2024

#### 19 The purposes for which the funds are

##### *Unrestricted and designated funds:-*

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

##### *Restricted funds:-*

Restricted Revenue Funds:

Restricted funds are funds that donors have given for a particular purpose and/or project as outlined by donors and may include other connected costs. The aim and use of each restricted fund are detailed in the notes of the financial statements.

#### 20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

*This analysis is classified by conventional nominal descriptions and not by activity.*

### 21 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Small donations individually less than £1000	21,996	-	21,996	19,232
Just Giving - anonymous donors	2,329	-	2,329	-
CLS UK	1,000	-	1,000	-
In Memory	13,786	-	13,786	13,387
<b>Total donations and gifts from individuals</b>	<b>39,111</b>	<b>-</b>	<b>39,111</b>	<b>32,619</b>

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
	2023	2023	2023	
	£	£	£	
Prior year	32,619	-	32,619	
	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Legacies receivable				
Late CH	-	-	-	2,218
<b>Total legacies receivable</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,218</b>

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior year	2,218	-	2,218

## Ocular Melanoma UK

### Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Arnold Clark	-	-	-	1,000
Delcath Systems Ltd	-	11,000	11,000	13,100
Immunocore Limited	-	32,000	32,000	41,100
National Lottery	-	-	-	10,000
Vision Foundation	-	9,000	9,000	-
Alan Boswell Charity ALA	3,022	-	3,022	-
Souter Charitable Trust	-	3,000	3,000	-
TriSalus Life Science	-	3,000	3,000	-
Ideya Biosciences	-	3,000	3,000	-
<b>Total private sector revenue grants</b>	<b>3,022</b>	<b>61,000</b>	<b>64,022</b>	<b>65,200</b>

### Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
<b>Prior Year</b>	<b>-</b>	<b>65,200</b>	<b>65,200</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

### Total Donations, Grants and Legacies

		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
<i>Current year</i>		2024	2024	2024	2023
		£	£	£	£
<b>Total Donations, Grants and Legacies</b>	A1	<b>42,133</b>	<b>61,000</b>	<b>103,133</b>	<b>100,037</b>
<i>Prior year</i>		Unrestricted Funds 2023	Restricted Funds 2023	Prior Year Total Funds 2023	
		£	£	£	
<b>Total Donations, Grants and Legacies</b>	A1	<b>34,837</b>	<b>65,200</b>	<b>100,037</b>	

### 22 Income from charitable activities - Trading Activities

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
<i>Current year</i>		2024	2024	2024	2023
		£	£	£	£
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		325	-	325	141
<b>Total Primary purpose and ancillary trading</b>		<b>325</b>	<b>-</b>	<b>325</b>	<b>141</b>
<i>Prior year</i>		Prior Year Unrestricted Funds 2023	Prior Year Restricted Funds 2023	Prior Year Total Funds 2023	
		£	£	£	
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		141	-	141	
<b>Total Primary purpose and ancillary trading</b>		<b>141</b>	<b>-</b>	<b>141</b>	

## Ocular Melanoma UK

### Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

#### 23 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Total income from charitable trading	325	-	325	141
<b>Total from charitable activities</b> <b>A2</b>	<b>325</b>	<b>-</b>	<b>325</b>	<b>141</b>

#### Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Total income from charitable trading	141	-	141
Income from funders	-	-	-
	<b>141</b>	<b>-</b>	<b>141</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

### 24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Income from fundraising events	45,317	-	45,317	28,754
<b>Total from other activities</b>	<b>45,317</b>	<b>-</b>	<b>45,317</b>	<b>28,754</b>

### Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	28,754	-	28,754

## Ocular Melanoma UK

### Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

#### 25 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Gross wages and salaries - charitable activities	66,951	30,900	97,851	66,373
Defined contribution pension costs - charitable activities	3,886	-	3,886	4,195
Travel and Subsistence - Charitable Activities	747	-	747	1,079
Marketing and advertising of charitable services	118	-	118	1,595
Charitable activities costs	1,395	25,311	26,706	21,025
Training costs	-	-	-	-
<b>Total direct spending</b>	<b>73,097</b>	<b>56,211</b>	<b>129,308</b>	<b>94,267</b>

All the expenditure in the prior year was unrestricted.

<i>Prior Year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Gross wages and salaries - charitable activities	42,310	24,063	66,373
Defined contribution pension costs - charitable activities	4,195	-	4,195
Travel and Subsistence - Charitable Activities	1,079	-	1,079
Marketing and advertising of charitable services	1,595	-	1,595
Charitable activities costs	3,681	17,344	21,025
Training costs	-	-	-
<b>Total direct spending</b>	<b>52,860</b>	<b>41,407</b>	<b>94,267</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

### 26 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
<b><i>Employee costs not included in direct costs</i></b>				
Recruitment expenses	256	-	256	892
<b><i>Administrative overheads</i></b>				
Telephone, fax and internet	1,885	-	1,885	954
Stationery and printing	597	-	597	344
Membership subscriptions	2,662	-	2,662	2,262
Software licences and expenses	2,682	-	2,682	4,094
Sundry expenses	-	-	-	-
Insurance	907	-	907	862
<b><i>Professional fees paid to advisors other than the auditor or examiner</i></b>				
Accountancy fees other than examination or audit fees	1,772	-	1,772	1,469
Other legal and professional	5,363	-	5,363	3,119
<b><i>Financial costs</i></b>				
Bank charges	132	-	132	205
Depreciation & Amortisation in total for the period	243	-	243	529
<b>Support costs before reallocation</b>	<b>16,499</b>	<b>-</b>	<b>16,499</b>	<b>14,730</b>
<b>Total support costs - Current Year</b>	<b>16,499</b>	<b>-</b>	<b>16,499</b>	<b>14,730</b>

The basis of allocation of costs between activities is described under accounting policies  
All the expenditure in the prior year was unrestricted.

### 27 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Independent Examiner's fees	1,170	-	1,170	1,080
Trustees' Remuneration as detailed in note 8	-	-	-	29,708
<b>Total Governance costs</b>	<b>1,170</b>	<b>-</b>	<b>1,170</b>	<b>30,788</b>

All the expenditure in the prior year was unrestricted.

## Ocular Melanoma UK

### Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

#### 28 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024 £	2024 £	2024 £	2023 £
Total direct spending	<b>B2a</b>	73,097	56,211	129,308	94,267
Total charitable trading costs	<b>B2b</b>	34	-	34	46
Total support costs	<b>B2d</b>	16,499	-	16,499	14,730
Total Governance costs	<b>B2e</b>	1,170	-	1,170	30,788
<b>Total charitable expenditure</b>	<b>B2</b>	<b>90,800</b>	<b>56,211</b>	<b>147,011</b>	<b>139,831</b>
<i>Prior Year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2023 £	2023 £	2023 £	
Total direct spending	<b>B2a</b>	52,860	41,407	94,267	
Total charitable trading costs	<b>B2b</b>	46	-	46	
Total support costs	<b>B2d</b>	14,730	-	14,730	
Total Governance costs	<b>B2e</b>	30,788	-	30,788	
<b>Total charitable expenditure</b>	<b>B2</b>	<b>98,424</b>	<b>41,407</b>	<b>139,831</b>	

#### 29 Expenditure on raising funds and costs of investment management

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024 £	2024 £	2024 £	2023 £
Cost of fundraising activities		2,972	-	2,972	1,144
<b>Total fundraising costs</b>	<b>B1</b>	<b>2,972</b>	<b>-</b>	<b>2,972</b>	<b>1,144</b>

All the expenditure in the prior year was unrestricted.

**Ocular Melanoma UK**

England & Wales - Charity number 1147506

---

# Accounts

---

Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

OcuMel UK

Report and Accounts

31 March 2023

**OcuMel UK**

**Report and accounts for the year ended 31 March 2023**

**Contents**

	<b>Page</b>
<b>Charity information</b>	
<b>Trustees' Annual Report</b>	1
<b>Statement of directors' responsibilities</b>	1
<b>Independent Accountant's Report</b>	11
	13
<b><i>Funds Statements:-</i></b>	
Statement of Financial Activities	15
Statement of Financial Activities - Prior Year statement	16
Movements in funds	17
Income and Expenditure account	18
	18
<b>Balance sheet</b>	
<b>Notes to the accounts</b>	19
	20

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2023**

The Trustees present their Report and Accounts for the year ended 31 March 2023, which also comprises the Directors' Report required by the Companies Act 2006.

#### **Reference and administrative details**

##### ***The charity name.***

The legal name of the charity is:- OcuMel UK.

The charity is also known by its operating name, OcuMel UK.

##### ***The charity's areas operation and UK charitable registration.***

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

##### ***Legal structure of the charity***

The charity is constituted as a company limited by guarantee, registered under the Companies Acts .

The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

Updated Articles of Assosiation and Special Resolution are dated 21 November 2023

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

##### **The principal operating address, telephone number, email and web addresses of the charity are:-**

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address info@omuk.info

Web Address www.ocumeluk.org

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

**OcuMeI UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2023**

**The Trustees in office on the date the report was approved were:-**

Mr Neil Pearce  
Mrs Alison Benjamin  
Mrs Joanne Morgan - Chair  
Mr Gianfranco De Franco  
Mr Colin White  
Mrs Charlotte Edwards - Treasurer

**The following persons served as Trustees during the year ended 31 March 2023 :-**

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-.

<b>Name</b>	<b>Appointed</b>	<b>Resigned/Retired</b>
Mr Neil Pearce		
Mrs Alison Benjamin	23 February 2023	
Mrs Giuseppina Gumbs - CEO		31 March 2023
Mrs Joanne Morgan - Chair		
Mr Gianfranco De Franco		
Mr Colin White	30 March 2023	
Mrs Charlotte Edwards - Treasurer		

All the trustees are also members of the charity.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2023**

#### **Objects and activities of the charity**

##### ***The purposes of the charity.***

OcuMel UK is the only UK charity solely dedicated to supporting people affected by ocular melanoma. We have been supporting people since 2011 with this rare cancer so they could talk to others about their cancer diagnosis and adjust to life if they experience vision loss.

We are determined to drive improvements so that people can live and live well with ocular melanoma. This can be a devastating cancer so we are working to ensure people have access to effective treatments and that clear pathways are in place, all while striving to provide specialist support to people who need it.

##### **What is Ocular Melanoma?**

Ocular melanoma is a cancer of the eye.

- We know between 600-750 people a year will hear they have ocular melanoma and those people are likely to need support.
- We know we have hundreds of people in the UK living with ocular melanoma, who may need support adjusting to life after their diagnosis.
- We also know too many people (approx. one in every two people) will hear they need further treatment if the cancer spreads and that no one should face this time alone.

Ocular melanoma includes two cancers, conjunctival and uveal melanoma, which includes the iris, choroid or ciliary body. Both types of ocular melanoma can metastasise (spread) to other organs, with the liver typically involved in 90% of uveal melanoma cases.

If ocular melanoma spreads to another organ, it is currently incurable. There are some treatments that have the potential to extend life expectancy and improve quality of life for some patients, but some patients face difficulties in accessing these treatments.

Ocular melanoma is usually discovered during a routine eye examination, or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects cancer, they should urgently refer the patient to their local ophthalmology department, should they agree with the concern, they will refer to one of four specialist centres: Glasgow, Liverpool, Sheffield or London.

##### **Why is OcuMel UK needed?**

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming, that patients frequently report feeling totally isolated. OcuMel UK came about to provide both support and a voice for those with rare cancer. We bring people together across the country and provide UK specific information.

Ocular Melanoma patients are often excluded from skin melanoma trials, and with no meaningful drug therapy available to treat the condition there has been little progress made in the last 20 years. OcuMel UK is raising the profile of the disease within the medical community and decision makers. We work to improve patients' access to effective treatments, and eventually financially support research.

## OcuMel UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2023

#### Our aims and objectives

Our Vision is a world where people with ocular melanoma can live, and live well.

Our Mission is to advocate for change by uniting people against ocular melanoma cancers so that every person receives the treatment, information and support they need.

OcuMel UK's charitable objectives are:

1. To primarily promote and protect the physical and mental health of sufferers of ocular melanoma in the United Kingdom through the provision of support, education and practical advice.
2. To advance the education of the public (and in particular, medical professionals) on the subject of ocular melanoma.
3. To promote research for the public benefit on the subject of ocular melanoma and to publish the useful results.

A special resolution was passed on the 22nd Sept 2023 to reduce the wording of the charitable objects.

***The main activities undertaken during the year to further the charity's purpose for the public benefit.***

#### Our Performance & Achievements during 2022/2023

OcuMel UK provides members and others with current information and non-clinical advice and support through a wide variety of channels.

People tell us they wish they learnt about us when they were first diagnosed as they appreciate the information and support we provide. This means a great deal to them, so we have planned several projects to increase our reach so that once someone is diagnosed, they learn about OcuMel UK, the services we provide, and that we can encourage treatment pathways to be developed to ease the pressures people face. During the year, we supported our community by offering the following services:

##### **To Improve Support**

###### Emotional & Practical Support

We recruited a dedicated Helpline Advisor who provides emotional and practical support for patients and loved ones at the point of need, by phone and in our online community support groups.

###### Psychological Support

Continued to provide members with timely & funded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have. This allows patients and loved ones throughout the UK to access up to six funded sessions.

###### Health Information

Began working on a series of patient information booklets so that people have specific information about their condition, the treatments they may receive, and other much needed information about how to live well with ocular melanoma. We also produced a booklet that was written for patients by patients with tips on things they felt were important to newly diagnosed patients.

###### Community Support

Supported people through our online forums and at biweekly virtual meetings in response to patient feedback, as people talked of feeling isolated before finding OcuMel UK.

Our community support meetings are now hosted by two members of staff which allows people to talk more openly in separate breakout rooms. We were also joined by new volunteer Local Ambassadors who helped us bring people together for a coffee and much needed peer-to-peer support in their local area.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2023**

#### **To Build Knowledge**

##### **Conference**

Held our first in person annual conference since 2019, which was well attended by 69 attendees, plus guest speakers. We received incredibly positive feedback from those who were able to join us. We always ensure these talks are recorded and available after the event so the latest knowledge is easily shared.

##### **Website**

Regularly updated our informational website [www.ocumeluk.org](http://www.ocumeluk.org) delivering information on Ocular Melanoma, its available treatments, and sources of further information.

##### **Bulletins**

We produce a monthly newsletter to our members giving updates on our work, how to access the services we provide, and importantly, information on how people can share their experience with us or decision makers to drive improvements.

##### **Insight Meetings**

We held meetings online for our members to come together, talk through their experience, or learn about certain aspects of the condition by hearing from leaders in their field. We also held focus groups to learn about the information patients would have found useful which enabled us to ensure our patient literature was produced in conjunction with our community and contained relevant information.

##### **Advocacy**

NICE began reviewing whether a new drug should be made available to suitable people with uveal melanoma. This drug was the first systemic drug that had a positive impact at treating metastatic disease, so we felt it was vital to support this review. We involved our community at every stage by running focus groups, educational sessions and produced guides on how they could make a submission.

##### **Rare Community**

OcuMel UK are members of Cancer52 and Genetic Alliance and regularly attend NHS England Cancer Charity meetings so key messages can be communicated to our community, but also allows us to communicate the needs of people affected by ocular melanoma to decision makers.

## OcuMel UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2023

#### To Drive Research

##### Clinical Advisory Panel

Began working with a panel of 29 clinicians to help us work on areas that are important to patients, loved ones and to the NHS.

##### Research applications

We supported several research applications that we felt would benefit people and met with organisations interested in learning about the impact of this cancer. At times it was appropriate for us to lead those conversations, but where companies were interested in talking to patients directly, we reviewed the questions that would be asked, and offered our support to the people involved.

##### Data

We said we would ensure there was clear visibility of all clinical trials known to us and we have now shared this information on our website so it is easily accessible. We have also been working to improve the data routinely available to researchers and bodies such as NICE & SMC and will continue to push for better data collection and sharing of data so that the needs of patients are clearly understood.

##### Access to Medicines

We continued to build relationships with pharmaceutical companies who have an interest in this cancer to increase the number of trials available to people, and to increase the possibility of effective treatments being made available to people.

##### Patient Need

We have expanded our reach so that more organisations understand that the needs of rare cancer patients are not being met with the current focus on improving mortality in the UK. We do this through working with organisations who share common goals and enable us to have a voice at a national level.

All this was achieved with the support of our donors and everyone who fundraised for us. We are incredibly grateful to everyone for their efforts over this challenging year as it enabled us to continue our work and support people through some very difficult times.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2023**

#### **Structure, governance and management of the charity**

##### ***The methods used to recruit and appoint new charity trustees.***

###### **Governing Document**

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

###### **Management Committee**

The directors of the company are also charity trustees for the purposes of charity law. Our CEO is also a trustee of the charity, and this has been approved by the Charity Commission, all other Trustees give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 7 to the accounts. Trustees serve for up to three years and may be re-elected at Annual General Meeting.

The Board of Directors, together with the CEO, acts as the Management Committee.

###### **Trustee Induction**

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

###### **Organizational Structure**

The Management Committee is responsible for the strategic direction and policy of the charity. The CEO has delegated responsibility from the Board for the overall operation of the charity.

###### **Bankers**

CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ

National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House,  
Bairs Road, Middlesex, EN1 1FD

Shawbrook Bank, Lutea House, Warley Hill Business Park, The Drive, Great  
Warley, Brentwood, Essex CM13 3BE

**OcuMeI UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2023**

**Financial review**

***The charity's financial position at the end of the year ended 31 March 2023***

The financial position of the charity at 31 March 2023 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
<b>Net income</b>	(11,805)	(68,799)
Unrestricted Revenue Funds available for the general purposes of the charity	54,910	90,508
Restricted Revenue Funds	23,793	-
<b>Total Restricted Funds</b>	23,793	-
<b>Total Funds</b>	78,703	90,508

***Financial review of the position at the reporting date, 31 March 2023***

The trustees consider the financial performance by the charity during the year to have been satisfactory.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2023**

#### ***Policies on reserves***

This reserves policy aims to establish guidelines for the appropriate level of reserves that OcuMel UK should maintain. The reserves policy will help ensure that OcuMel UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks. The reserves policy will also provide transparency and accountability to OcuMel UK's stakeholders, including donors, volunteers, staff, and beneficiaries.

##### **Nature of reserves:**

For the purposes of this policy, reserves are defined as funds that are held in excess of the immediate needs of OcuMel UK. Reserves include both unrestricted and restricted funds.

##### **Reserves Guidelines:**

1. **Target Reserves:** OcuMel UK should maintain a target reserve level equivalent to at least six months of operating expenses. The target reserves will be reviewed annually and adjusted as needed based on OcuMel UK's financial situation, risks, and opportunities.
2. **Minimum Reserves:** OcuMel UK should maintain a minimum level of reserves that is equivalent to three months of operating expenses. The minimum reserves will be reviewed annually and adjusted as needed based on OcuMel UK's financial situation, risks, and opportunities.
3. **Use of Reserves:** Reserves should only be used for specific purposes, such as emergencies, unexpected expenses, or to support new initiatives. Reserves should not be used to cover ongoing operational deficits or to fund programs that are not sustainable.
4. **Investment of Reserves:** Reserves should be invested in a prudent manner that balances safety, liquidity, and yield. The investment strategy should be reviewed annually and adjusted as needed based on OcuMel UK's financial situation, risks, and opportunities.
5. **Reporting on Reserves:** OcuMel UK will report annually on the status of its reserves in its financial statements. This reserves policy ensures that OcuMel UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks. The policy provides guidelines for the appropriate level of reserves, the use and investment of reserves, and reporting on reserves. The policy will be reviewed annually and adjusted as needed based on OcuMel UK's financial situation, risks, and opportunities.

#### ***Availability and adequacy of assets of each of the funds***

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2023**

#### ***Plans For the Future***

##### **Summary of plans for the future and the trustees' perspective of the future direction of the charity.**

We strive to improve the care, treatment, and support patients receive, and we will continue our work so that once someone is diagnosed, they learn about our services and that treatment pathways are developed to ease the pressures we know people face.

We identified several ways to reduce these pressures, building our small charity to help people and their families through these difficult times.

In addition to the services outlined earlier in this report, we will continue to focus efforts to

1. Reduce delays in accessing treatment for metastatic disease and
2. Increase our services that reduce isolation and distress.

We will do this by

- Ensuring all clinical trials known to us are shared on our website. This is incredibly important as there is no other resource that shows all the trials that could be useful to our patients.
- Representing our community at NICE, SMC & NHS reviews so that treatments that can help our community become available to the patients that need them.
- Developing a suite of literature with information that our community feels is important, and have this recognised as a trusted source of health information by becoming PIF-TICK accredited. We are so pleased to be working with excellent medical writers, clinicians, and patients so we produce valuable resources about this rare cancer.
- Hosting a conference for people to learn more about clinical developments in this area, information on how people can live well with this cancer, and importantly to bring people together for peer-to-peer support.
- Increasing the number of volunteers, including our local ambassadors so local meetings can take place around the country.
- Using all the resources we have available so that we are not held back because of financial constraints. Our support is important to people, so we will ensure our small team is correctly placed to achieve the plans outlined in our 3-year strategy.

Everything OcuMel UK has achieved has been through sheer dedication and a passion to make a real change to the lives of those affected by this dreadful cancer.

We will continue until we have a world where people with ocular melanoma can live, and live well.

#### **Details of The Independent Examiner**

Tracey Pritchard BA FCA

Member of Chartered Accountant

255 Poulton Road

Wallasey

Merseyside

CH44 4BT

## OcuMeI UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2023

#### Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

**OcuMel UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2023**

**Method of preparation of accounts - Small company provisions**

The financial statements are set out on pages 15 to 33.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 18/12/ 2023.



MRS C EDWARDS  
Director and Trustee

## OcuMel UK

### Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2023

I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 33 for the year ended 31 March 2023 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 20.

#### Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

## OcuMeI UK

### Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

This report was signed on 18/12/ 2023

**OcuMel UK - Statement of Financial Activities for the year ended 31 March 2023**

**Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2023, as required by the Companies Act 2006)**

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
<b>Income &amp; Endowments from:</b>					
Donations & Legacies	A1	34,837	65,200	100,037	28,115
Charitable activities	A2	141	-	141	497
Other trading activities	A3	28,754	-	28,754	43,478
Investments	A4	238	-	238	-
<b>Total income</b>	<b>A</b>	<b>63,970</b>	<b>65,200</b>	<b>129,170</b>	<b>72,090</b>
<b>Expenditure on:</b>					
Raising funds	B1	1,144	-	1,144	1,058
Charitable activities	B2	98,424	41,407	139,831	139,831
<b>Total expenditure</b>	<b>B</b>	<b>99,568</b>	<b>41,407</b>	<b>140,975</b>	<b>140,889</b>
<b>Net income for the year</b>		<b>(35,598)</b>	<b>23,793</b>	<b>(11,805)</b>	<b>(68,799)</b>
<b>Transfers between funds</b>	<b>C</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income after transfers</b>	<b>A-B-C</b>	<b>(35,598)</b>	<b>23,793</b>	<b>(11,805)</b>	<b>(68,799)</b>
<b>Net movement in funds</b>		<b>(35,598)</b>	<b>23,793</b>	<b>(11,805)</b>	<b>(68,799)</b>
<b>Reconciliation of funds:-</b>					
<b>Total funds brought forward</b>		90,508	-	90,508	159,307
<b>Total funds carried forward</b>		<b>54,910</b>	<b>23,793</b>	<b>78,703</b>	<b>90,508</b>

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

**The notes attached on pages 20 to 33 form an integral part of these accounts.**

**OcuMel UK - Statement of Financial Activities for the year ended 31 March 2023**

**OcuMel UK - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP**

	SORP Ref	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
<b>Income &amp; Endowments from:</b>				
Donations & Legacies	A1	28,115	-	28,115
Charitable activities	A2	497	-	497
Other trading activities	A3	43,478	-	43,478
<b>Total income</b>	<b>A</b>	<u>72,090</u>	<u>-</u>	<u>72,090</u>
<b>Expenditure on:</b>				
Raising funds	B1	1,058	-	1,058
Charitable activities	B2	128,725	11,106	139,831
<b>Total expenditure</b>	<b>B</b>	<u>129,783</u>	<u>11,106</u>	<u>140,889</u>
Net gains on investments	B4	-	-	-
<b>Net income for the year</b>		(57,693)	(11,106)	(68,799)
Transfers between funds	C	(344)	344	-
<b>Net income after transfers</b>		<u>(58,037)</u>	<u>(10,762)</u>	<u>(68,799)</u>
<b>Net movement in funds</b>		<u>(58,037)</u>	<u>(10,762)</u>	<u>(68,799)</u>
<b>Reconciliation of funds:-</b>				
<b>Total funds brought forward</b>		148,545	10,762	159,307
<b>Total funds carried forward</b>		<u>90,508</u>	<u>-</u>	<u>90,508</u>

**OcuMel UK - Statement of Financial Activities for the year ended 31 March 2023**

**OcuMel UK - Resources applied in the year ended 31 March 2023 towards fixed assets for Charity use:-**

	2023 £	2022 £
Funds generated in the year as detailed in the SOFA	(11,805)	(68,799)
Resources applied on functional fixed assets	(427)	-
Other applications of funds	-	-
<b>Net resources available to fund charitable activities</b>	<u><b>(12,232)</b></u>	<u><b>(68,799)</b></u>

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 20 to 33 form an integral part of these accounts.

**Movements in revenue and capital funds for the year ended 31 March 2023**

**Revenue accumulated funds**

	Unrestricted Funds 2023 £	Restricted Funds 2023 £	Total Funds 2023 £	Last year Total Funds 2022 £
Accumulated funds brought forward	90,508	-	90,508	159,307
Recognised gains and losses before transfers	<u>(35,598)</u>	<u>23,793</u>	<u>(11,805)</u>	<u>(68,799)</u>
	<b>54,910</b>	<b>23,793</b>	<b>78,703</b>	<b>90,508</b>
(From)/To unrestricted revenue funds	-	-	-	-
<b>Closing revenue funds</b>	<u><b>54,910</b></u>	<u><b>23,793</b></u>	<u><b>78,703</b></u>	<u><b>90,508</b></u>

**Summary of funds**

	Unrestricted and Designated funds 2023 £	Restricted Funds 2023 £	Total Funds 2023 £	Last Year Total Funds 2022 £
Revenue accumulated funds	54,910	23,793	78,703	90,508

The notes attached on pages 20 to 33 form an integral part of these accounts.

**OcuMel UK - Statement of Financial Activities for the year ended 31 March 2023**

**OcuMel UK  
Income and Expenditure Account for the year ended 31 March 2023 as required by the  
Companies Act 2006**

	2023	2022
	£	£
<i>Income</i>		
Income from operations	128,932	72,090
Investment income		
Interest receivable	238	-
<b>Gross income in the year before exceptional items</b>	<u>129,170</u>	<u>72,090</u>
<b>Gross income in the year including exceptional items</b>	<u>129,170</u>	<u>72,090</u>
<i>Expenditure</i>		
Charitable expenditure, excluding depreciation and amortisation	108,514	109,751
Depreciation and amortisation	529	827
Fundraising costs	1,144	1,058
Governance costs	30,788	29,253
Realised losses on disposals of social investments which are programme related	-	-
<b>Total expenditure in the year</b>	<u>140,975</u>	<u>140,889</u>
<b>Net income before tax in the financial year</b>	<u>(11,805)</u>	<u>(68,799)</u>
Tax on surplus on ordinary activities	-	-
<b>Net income after tax in the financial year</b>	<u>(11,805)</u>	<u>(68,799)</u>
<b>Retained surplus for the financial year</b>	<u>(11,805)</u>	<u>(68,799)</u>

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

**The notes attached on pages 20 to 33 form an integral part of these accounts.**

OcuMel UK - Balance Sheet as at 31 March 2023

	SORP Note Ref	2023 £	2022 £
<b>Fixed assets</b>			
Tangible assets	10 A2	481	583
<b>Current assets</b>			
Stocks	B		
Debtors	12 B1	2,108	1,706
Cash at bank and in hand	B2	-	-
	B4	77,236	91,778
<b>Total current assets</b>		<u>79,344</u>	<u>93,484</u>
<b>Creditors: amounts falling due within one year</b>	13 C1	<u>(1,122)</u>	<u>(3,559)</u>
<b>Net current assets</b>		78,222	89,925
<b>The total net assets of the charity</b>		<u><u>78,703</u></u>	<u><u>90,508</u></u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

<b>Restricted funds</b>			
Restricted Revenue Funds	17 D2	23,793	-
<b>Unrestricted Funds</b>		23,793	-
Unrestricted Revenue Funds	17 D3	54,910	90,508
<b>Total charity funds</b>		<u>54,910</u>	<u>90,508</u>
		<u><u>78,703</u></u>	<u><u>90,508</u></u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



MRS C EDWARDS

Trustee

Approved by the board of trustees on 18/12/ 2023

The notes attached on pages 20 to 33 form an integral part of these accounts.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2023

#### 1 Accounting policies

##### *Policies relating to the production of the accounts.*

###### **Basis of preparation and accounting convention**

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

###### **Risks and future assumptions**

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the OcuMel UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

###### **Accounting for deferred income and income received in advance**

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

## Notes to the Accounts for the year ended 31 March 2023

### Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

### ***Policies relating to assets, liabilities and provisions and other matters.***

#### ***Tangible fixed assets***

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

#### **Stocks and work in progress**

Stock is valued at the lower of cost and net realisable value.

#### **Fund Accounting**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2023

#### 2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

#### 3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

#### 4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

#### 5 Net surplus before tax in the financial year

	2023	2022
	£	£
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	529	827
Trustees' Remuneration as detailed in note 8	29,708	28,293
Pension costs	4,195	3,256
	<u>4,195</u>	<u>3,256</u>

#### 6 Staff costs and emoluments

##### Salary costs

	2023	2022
	£	£
Gross Salaries excluding trustees and key management personnel	66,373	44,519
Employer's operating costs of defined contribution pension schemes	4,195	3,256
Trustees' Remuneration as detailed in note 8	29,708	28,293
<b>Total salaries, wages and related costs</b>	<u><b>100,276</b></u>	<u><b>76,068</b></u>

The average number of full time staff employed in the year was	1	3
The estimated full time equivalent number of all staff employed in the year was	3	2

##### The estimated equivalent number of full time staff deployed in different activities in the year was:-

Engaged on charitable activities	2	2
<b>The estimated full time equivalent number of all staff employed as above</b>	<u><b>3</b></u>	<u><b>2</b></u>

The details of remuneration paid to trustees is shown in note 8

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

#### 7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2023

#### 8 Remuneration and payments to Trustees and persons connected with them

	2023	2022
	£	£
<i>Remuneration payable to trustees or connected persons</i>		
Trustee 1	29,708	28,293
<b>Total remuneration</b>	<b>29,708</b>	<b>28,293</b>

More detailed information in the Management Committee section on page 7.

#### 9 Trustees' expenses

No trustee expenses were incurred, either in the current or prior year.

#### 10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
At 1 April 2022	-	3,125	-	3,125
Additions	-	427	-	427
<b>At 31 March 2023</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
At 1 April 2022	-	2,542	-	2,542
Charge for the year	-	529	-	529
<b>At 31 March 2023</b>	<b>-</b>	<b>3,071</b>	<b>-</b>	<b>3,071</b>
<b>Net book value</b>				
At 31 March 2023	-	481	-	481
At 31 March 2022	-	583	-	583
 <i>Prior Year</i>				
	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
01 April 2021	-	3,125	-	3,125
Additions	-	-	-	-
<b>31 March 2022</b>	<b>-</b>	<b>3,125</b>	<b>-</b>	<b>3,125</b>
<b>Depreciation</b>				
01 April 2021	-	1,715	-	1,715
Charge for the year	-	827	-	827
<b>31 March 2022</b>	<b>-</b>	<b>2,542</b>	<b>-</b>	<b>2,542</b>
<b>Net book value</b>				
31 March 2022	-	583	-	583
31 March 2021	-	1,410	-	1,410

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2023

<b>11 Stocks &amp; Work in Progress</b>	<b>2023</b>	<b>2022</b>
	£	£
Stocks before write downs	2,108	1,706
	<u>2,108</u>	<u>1,706</u>
<b>12 Debtors</b>	<b>2023</b>	<b>2022</b>
	£	£
Prepayments and accrued income	-	-
	<u>-</u>	<u>-</u>
<b>13 Creditors: amounts falling due within one year</b>	<b>2023</b>	<b>2022</b>
	£	£
Trade creditors	162	2,599
Accruals	960	960
	<u>1,122</u>	<u>3,559</u>
<b>14 Income and Expenditure account summary</b>	<b>2023</b>	<b>2022</b>
	£	£
At 1 April 2022	90,508	159,307
Surplus after tax for the year	(11,805)	(68,799)
At 31 March 2023	<u>78,703</u>	<u>90,508</u>

### 15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

### 16 Particulars of how particular funds are represented by assets and liabilities

<b>At 31 March 2023</b>	<b>Unrestricted funds</b>	<b>Designated funds</b>	<b>Restricted funds</b>	<b>Total Funds</b>
	£	£	£	£
Tangible Fixed Assets	481	-	-	481
Current Assets	55,551	-	23,793	79,344
Current Liabilities	(1,122)	-	-	(1,122)
	<u>54,910</u>	<u>-</u>	<u>23,793</u>	<u>78,703</u>
<b>At 1 April 2022</b>	<b>Unrestricted funds</b>	<b>Designated funds</b>	<b>Restricted funds</b>	<b>Total Funds</b>
	£	£	£	£
Tangible Fixed Assets	583	-	-	583
Current Assets	93,484	-	-	93,484
Current Liabilities	(3,559)	-	-	(3,559)
	<u>90,508</u>	<u>-</u>	<u>-</u>	<u>90,508</u>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2023

#### 17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2022	Movement in funds in 2023	Transfers between funds in 2023	Funds carried forward to 2024
	£	See Note 18 £	£	£
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	90,508	(35,598)	-	54,910
<b>Total unrestricted and designated funds</b>	<b>90,508</b>	<b>(35,598)</b>	<b>-</b>	<b>54,910</b>
<b>Restricted funds:-</b>				
Patient folder		3,675	-	3,675
Patient Information to PifTick standard	-	9,766	-	9,766
Helpline Advisor Role	-	1,457	-	1,457
Psychological Support	-	2,645	-	2,645
Helpline Support	-	6,250	-	6,250
<b>Total restricted funds</b>	<b>-</b>	<b>23,793</b>	<b>-</b>	<b>23,793</b>
<b>Total charity funds</b>	<b>90,508</b>	<b>(11,805)</b>	<b>-</b>	<b>78,703</b>

#### 18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2023 £	2023 £	2023 £	2023 £
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	63,970	(99,568)	-	(35,598)
<b>Restricted funds:-</b>				
Conference and educational events	9,800	(9,800)	-	-
Patient folder	4,200	(525)	-	3,675
Patient Information to PifTick standard	24,000	(14,234)	-	9,766
Helpline Advisor Role	16,200	(14,743)	-	1,457
Psychological Support	4,750	(2,105)	-	2,645
Helpline Support	6,250	-	-	6,250
	<b>129,170</b>	<b>(140,975)</b>	<b>-</b>	<b>(11,805)</b>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2023

#### 19 The purposes for which the funds are

##### *Unrestricted and designated funds:-*

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

##### *Restricted funds:-*

Restricted Revenue Funds:

Restricted funds are funds that donors have given for a particular purpose and/or project as outlined by donors and may include other connected costs. The aim and use of each restricted fund are detailed in the notes of the financial statements.

#### 20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

OcuMeI UK

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

*This analysis is classified by conventional nominal descriptions and not by activity.*

21 Donations, Grants and Legacies

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
<b>Donations and gifts from individuals</b>				
Small donations individually less than £1000	19,232	-	19,232	22,776
In Memory	13,387	-	13,387	4,379
<b>Total donations and gifts from individuals</b>	<b>32,619</b>	<b>-</b>	<b>32,619</b>	<b>27,155</b>

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
<b>Prior year</b>	<b>27,155</b>	<b>-</b>	<b>27,155</b>

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
<b>Legacies receivable</b>				
Late CH	2,218	-	2,218	-
<b>Total legacies receivable</b>	<b>2,218</b>	<b>-</b>	<b>2,218</b>	<b>-</b>

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
<b>Prior year</b>	<b>-</b>	<b>-</b>	<b>-</b>

OcuMeI UK

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Revenue grants from government and public bodies				
Department for Work & Pension	-	-	-	960
<b>Total public sector revenue grants</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>960</b>

Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
Prior Year	960	-	960

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Revenue grants and donations from non public bodies				
Arnold Clark	-	1,000	1,000	-
Delcath Systems Ltd	-	13,100	13,100	-
Immunocore Limited	-	41,100	41,100	-
National Lottery	-	10,000	10,000	-
<b>Total private sector revenue grants</b>	<b>-</b>	<b>65,200</b>	<b>65,200</b>	<b>-</b>

Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
Prior Year	-	-	-

OcuMeI UK

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

**Total Donations, Grants and Legacies**

		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
<i>Current year</i>		2023	2023	2023	2022
		£	£	£	£
<b>Total Donations, Grants and Legacies</b>	A1	<b>34,837</b>	<b>65,200</b>	<b>100,037</b>	<b>28,115</b>
<i>Prior year</i>		Unrestricted Funds 2022	Restricted Funds 2022	Prior Year Total Funds 2022	
		£	£	£	
<b>Total Donations, Grants and Legacies</b>	A1	<b>28,115</b>	<b>-</b>	<b>28,115</b>	

**22 Income from charitable activities - Trading Activities**

<i>Current year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
		2023	2023	2023	2022
		£	£	£	£
Primary purpose and ancillary trading					
Sale of goods and services in accordance with the charity's objects		141	-	141	497
<b>Total Primary purpose and ancillary trading</b>		<b>141</b>	<b>-</b>	<b>141</b>	<b>497</b>

**23 Total Income from charitable activities**

<i>Current year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Total income from charitable trading		141	-	141	497
<b>Total from charitable activities</b>	<b>A2</b>	<b>141</b>	<b>-</b>	<b>141</b>	<b>497</b>

OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Income from fundraising events	28,754	-	28,754	43,478
<b>Total from other activities</b> <b>A3</b>	<b>28,754</b>	<b>-</b>	<b>28,754</b>	<b>43,478</b>

Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	43,478	-	43,478

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

#### 25 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Gross wages and salaries - charitable activities	42,310	24,063	66,373	44,519
Defined contribution pension costs - charitable activities	4,195	-	4,195	3,256
Travel and Subsistence - Charitable Activities	1,079	-	1,079	-
Marketing and advertising of charitable services	1,595	-	1,595	5,743
Charitable activities costs	3,681	17,344	21,025	14,741
Training costs	-	-	-	236
<b>Total direct spending</b>	<b>52,860</b>	<b>41,407</b>	<b>94,267</b>	<b>68,495</b>

All the expenditure in the prior year was unrestricted.

<i>Prior Year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2022	2022	2022
	£	£	£
Gross wages and salaries - charitable activities	36,738	7,781	44,519
Defined contribution pension costs - charitable activities	3,256	-	3,256
Travel and Subsistence - Charitable Activities	-	-	-
Marketing and advertising of charitable services	5,743	-	5,743
Charitable activities costs	11,416	3,325	14,741
Training costs	236	-	236
<b>Total direct spending</b>	<b>57,389</b>	<b>11,106</b>	<b>68,495</b>

#### 26 Expenditure on charitable activities- Grant funding of activities

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Grants made to individuals	-	-	-	30,000
Grants made to organisations	-	-	-	-
<b>Total grantmaking costs</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>30,000</b>

## OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

### 27 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
<b><i>Employee costs not included in direct costs</i></b>				
Recruitment expenses	892	-	892	-
<b><i>Administrative overheads</i></b>				
Telephone, fax and internet	954	-	954	777
Stationery and printing	344	-	344	489
Membership subscriptions	2,262	-	2,262	1,258
Software licences and expenses	4,094	-	4,094	3,721
Sundry expenses	-	-	-	117
Insurance	862	-	862	659
<b><i>Professional fees paid to advisors other than the auditor or examiner</i></b>				
Accountancy fees other than examination or audit fees	1,469	-	1,469	1,710
Other legal and professional	3,119	-	3,119	2,327
<b><i>Financial costs</i></b>				
Bank charges	205	-	205	198
Depreciation & Amortisation in total for the period	529	-	529	827
<b>Support costs before reallocation</b>	<b>14,730</b>	<b>-</b>	<b>14,730</b>	<b>12,083</b>
<b>Total support costs - Current Year</b>	<b>14,730</b>	<b>-</b>	<b>14,730</b>	<b>12,083</b>
				-
The basis of allocation of costs between activities is described under accounting policies				-
All the expenditure in the prior year was unrestricted.				-

### 28 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Independent Examiner's fees	1,080	-	1,080	960
Trustees' Remuneration as detailed in note 8	29,708	-	29,708	28,293
<b>Total Governance costs</b>	<b>30,788</b>	<b>-</b>	<b>30,788</b>	<b>29,253</b>

All the expenditure in the prior year was unrestricted.

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

#### 29 Total Charitable expenditure

		Current year	Current year	Current year	Prior Year
		Unrestricted	Restricted	Total Funds	Total Funds
<i>Current Year</i>		Funds	Funds	Total Funds	Total Funds
		2023	2023	2023	2022
		£	£	£	£
Total direct spending	<b>B2a</b>	52,860	41,407	94,267	68,495
Total charitable trading costs	<b>B2b</b>	46	-	46	-
Total grantmaking costs	<b>B2c</b>	-	-	-	30,000
Total support costs	<b>B2d</b>	14,730	-	14,730	12,083
Total Governance costs	<b>B2e</b>	30,788	-	30,788	29,253
<b>Total charitable expenditure</b>	<b>B2</b>	<b>98,424</b>	<b>41,407</b>	<b>139,831</b>	<b>139,831</b>
<i>Prior Year</i>		Prior Year	Prior Year	Prior Year	
		Unrestricted	Restricted	Total Funds	
		Funds	Funds	Total Funds	
		2022	2022	2022	
		£	£	£	
Total direct spending	<b>B2a</b>	57,389	11,106	68,495	
Total grantmaking costs	<b>B2c</b>	30,000	-	30,000	
Total support costs	<b>B2d</b>	12,083	-	12,083	
Total Governance costs	<b>B2e</b>	29,253	-	29,253	
Movements in provisions and commitments	<b>B2e</b>	-	-	-	
<b>Total charitable expenditure</b>	<b>B2</b>	<b>128,725</b>	<b>11,106</b>	<b>139,831</b>	

#### 30 Expenditure on raising funds and costs of investment management

		Current year	Current year	Current year	Prior Year
		Unrestricted	Restricted	Total Funds	Total Funds
<i>Current Year</i>		Funds	Funds	Total Funds	Total Funds
		2023	2023	2023	2022
		£	£	£	£
Cost of fundraising activities		1,144	-	1,144	1,058
<b>Total fundraising costs</b>	<b>B1</b>	<b>1,144</b>	<b>-</b>	<b>1,144</b>	<b>1,058</b>

All the expenditure in the prior year was unrestricted.

**Ocular Melanoma UK**

England & Wales - Charity number 1147506

---

# Accounts

---

Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

OcuMel UK  
Report and Accounts  
31 March 2022

**OcuMel UK**

**Report and accounts for the year ended 31 March 2022**

**Contents**

	<b>Page</b>
<b>Charity information</b>	1
<b>Trustees' Annual Report</b>	1
<b>Statement of directors' responsibilities</b>	9
<b>Independent Accountant's Report</b>	11
<b><i>Funds Statements:-</i></b>	
Statement of Financial Activities	13
Movements in funds	14
Income and Expenditure account	15
<b>Balance sheet</b>	16
<b>Notes to the accounts</b>	17

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

The Trustees present their Report and Accounts for the year ended 31 March 2022, which also comprises the Directors' Report required by the Companies Act 2006.

#### **Reference and administrative details**

##### ***The charity name.***

The legal name of the charity is:- OcuMel UK.

The charity is also known by its operating name, OcuMel UK.

##### ***The charity's areas operation and UK charitable registration.***

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

##### ***Legal structure of the charity***

The charity is constituted as a company limited by guarantee, registered under the Companies Acts .

The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

##### **The principal operating address, telephone number, email and web addresses of the charity are:-**

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address info@omuk.info

Web Address www.ocumeluk.org

The registered office of the charity for Companies Act purposes is:-

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **The Trustees in office on the date the report was approved were:-**

Mr Neil Pearce - Chair  
Mrs Giuseppina Gumbs - CEO  
Mrs Joanne Morgan  
Mr Gianfranco De Franco  
Mrs Charlotte Edwards - Treasurer

#### **The following persons served as Trustees during the year ended 31 March 2022 :-**

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-.

<b><i>Name</i></b>	<b><i>Appointed</i></b>	<b><i>Resigned/Retired</i></b>
Mr Neil Pearce - Chair		
Mrs Giuseppina Gumbs - CEO		
Mrs Joanne Morgan		
Mr Gianfranco De Franco		
Mrs Charlotte Edwards - Treasurer		

All the trustees are also members of the charity.

## **OcuMel UK**

Company Registration Number - 8013670

## **Trustees' Annual Report for the year ended 31 March 2022**

### **Objects and activities of the charity**

#### ***The purposes of the charity.***

##### **What is Ocular Melanoma?**

Ocular melanoma is a cancer of the eye.

- We know between 600-750 people a year will hear they have ocular melanoma and those people are likely to need support.
- We know we have hundreds of people in the UK living with ocular melanoma, who may need support adjusting to life after their diagnosis.
- We also know too many people (approx. one in every two people) will hear they need further treatment if the cancer spreads and that no one should face this time alone.

Ocular melanoma includes two cancers, conjunctival and uveal melanoma, which includes the iris, choroid or ciliary body.

Both types of ocular melanoma can metastasise (spread) to other organs, with the liver typically involved in 90% of uveal melanoma cases. If ocular melanoma spreads to another organ, it is currently incurable. There are treatments available that have the potential to extend life expectancy and improve quality of life for some patients.

Ocular melanoma is usually discovered during a routine eye examination, or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects cancer, they should urgently refer the patient to their local ophthalmology department, should they agree with the concern, they will refer to one of four specialist centres: Glasgow, Liverpool, Sheffield or London.

##### **Why is OcuMel UK needed?**

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming, that patients frequently report feeling totally isolated. OcuMel UK came about to provide both support and a voice for those with rare cancer. We bring people together across the country and provide UK-specific information.

Ocular Melanoma patients are often excluded from melanoma trials, and with no meaningful drug therapy available to treat the condition there has been very little progress made in the last 20 years. OcuMel UK is raising the profile of the disease within the medical community. We hope to improve patients' access to treatment, and eventually to support ocular melanoma research.

Support in other countries can be limited and so information provided through our website is available to all and can be translated to other languages. Support is also given to patients outside the UK on our forums and through our helpline in English. Where country specific information is needed, we can often signpost patients to other community members for assistance.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **Our aims and objectives**

Our Vision is a world where people with ocular melanoma can live, and live well.

Our Mission is to advocate for change by uniting the wider community against ocular melanoma cancers so that every person receives the treatment, information and support they need.

Our objectives:

OcuMel UK's charitable objectives are:

1. To primarily promote and protect the physical and mental health of sufferers of ocular melanoma in the United Kingdom through the provision of support, education and practical advice.
2. To advance the education of the public (and in particular, medical professionals) on the subject of ocular melanoma.
3. To promote research for the public benefit on the subject of ocular melanoma and to publish the useful results.

#### ***The main activities undertaken during the year to further the charity's purpose for the public benefit.***

OcuMel UK provides members and others with current information and non-clinical advice and support through a wide variety of channels. During the year, we supported our community by offering the following services:

##### **To Improve Support**

###### **Helpline**

We provided emotional and practical support managed by experienced staff and helpline volunteers for patients and loved ones at the point of need.

###### **Emotional Support**

In addition to the support offered through our Helpline, members can also access timely & funded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have.

###### **Patient Literature**

We began to work on a series of patient information so that people have specific information about their condition, the treatments they may receive and other much needed information about how to live well with ocular melanoma.

###### **Advocacy**

OcuMel UK advocated for our members individually and at a community level. We have done this by issuing surveys and making submissions to relevant bodies on behalf of our membership, so issues that affected patients could be raised. Importantly, we were the patient voice throughout a technology appraisal, led by NICE, to understand whether a new drug should be offered to patients. We ran focus groups, produced guides and educational sessions so that people's thoughts were included.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **To Build Knowledge**

##### **Website**

We operate our informational website [www.ocumeluk.org](http://www.ocumeluk.org) delivering information on Ocular Melanoma, its available treatments, and sources of further information.

##### **Bulletins**

We email a monthly newsletter to our members with updates on our work, how to access the services we provide and importantly, we provide information on how people can share their experience to shape future improvements.

##### **Meetings**

We arrange weekly meetings online for our members to come together and either talk through their experience or learn about certain aspects of the condition by hearing from leaders in their field.

##### **Rare Community**

OcuMel UK are members of Cancer52 and Genetic Alliance and regularly attend NHS England Cancer Charity meetings so key messages can be communicated to our community, but also so their needs are communicated to decision makers.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **To Drive Research**

##### Data

We have worked with Public Health England to improve the datasets held about Eye Cancers so that existing data could be used to understand more about this disease.

##### Access to Medicines

We have built relationships with pharmaceutical companies with an interest in OM and completed a Fellowship into Early Access Medicine schemes, run by Clinigen.

##### Patient Need

OcuMel UK have presented the needs of rare cancer patients to BIVDA (British In Vitro Diagnostics Association), so they could understand some of the challenges faced by rare cancer patients and drive improvements in this area.

We are incredibly grateful to our fundraisers and donors for their efforts over this challenging year. It enabled us to continue our work and support people throughout the year.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **Structure, governance and management of the charity**

##### ***The methods used to recruit and appoint new charity trustees.***

##### **Governing Document**

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

##### **Management Committee**

The directors of the company are also charity trustees for the purposes of charity law. Our CEO is also a trustee of the charity, and this has been approved by the Charity Commission, all other Trustees give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 7 to the accounts. Trustees serve for up to three years and may be re-elected at Annual General Meeting.

The Board of Directors, together with the CEO, acts as the Management Committee.

##### **Trustee Induction**

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

##### **Organizational Structure**

The Management Committee is responsible for the strategic direction and policy of the charity. The CEO has delegated responsibility from the Board for the overall operation of the charity.

##### **Bankers**

CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ

National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House,  
Bairs Road, Middlesex, EN1 1FD

Shawbrook Bank, Lutea House, Warley Hill Business Park, The Drive, Great  
Warley, Brentwood, Essex CM13 3BE

## OcuMel UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2022

#### Financial review

##### *The charity's financial position at the end of the year ended 31 March 2022*

The financial position of the charity at 31 March 2022 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2022	2021
	£	£
<b>Net income</b>	(68,799)	9,422
Unrestricted Revenue Funds available for the general purposes of the charity	90,508	148,545
Restricted Revenue Funds	-	10,762
<b>Total Restricted Funds</b>	-	10,762
<b>Total Funds</b>	90,508	159,307

##### *Financial review of the position at the reporting date, 31 March 2022*

The trustees consider the financial performance by the charity during the year to have been satisfactory.

##### ***Policies on reserves***

As a small charity with very variable income the charity's main priority is to maintain its long term financial viability. With this in mind, the charity's policy is to build and retain sufficient reserves to meet committed expenditure for 12 months ahead.

##### ***Availability and adequacy of assets of each of the funds***

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

## **OcuMel UK**

Company Registration Number - 8013670

## **Trustees' Annual Report for the year ended 31 March 2022**

### ***Plans For the Future***

#### **Summary of plans for the future and the trustees' perspective of the future direction of the charity.**

We strive to improve the care, treatment and support patients receive.

We need to make sure that once someone has been diagnosed, they learn about OcuMel UK, the services we provide, and that treatment pathways are developed to ease the pressures that we know people face. We have identified several ways to reduce these pressures, and over the coming years we will build our small charity so we can help people and their families through these difficult times.

In addition to the services already outlined and we will focus efforts on the following areas  
-reducing delays accessing treatment for metastatic disease  
-reducing isolation and distress

We will do this by ensuring there is clear visibility of all clinical trials known to us on our website and we will support clinicians with any difficulties. NICE began reviewing whether a new treatment should be available to patients with uveal melanoma, and so we will continue to represent our community throughout this in-depth process.

We have begun working on patient literature with a booklet for people with metastatic disease and this will be followed by booklets on other aspects of the condition led by priority need as identified from our focus groups. We are so pleased to be working with excellent medical writers, clinicians, and patients so we can produce valuable resources about this rare cancer.

Our annual conferences have always been a superb source of information and support to our community, so we look forward to hosting a virtual conference, with an in-person conference likely to follow the following year. Our community had missed these events during the pandemic and so we are delighted we will hear from many expert speakers from around the country.

So that we can expand the services we provide and expand our reach, we will grow our team, so we are better resourced. Our income reduced significantly during the pandemic so some of our resource will focus efforts on ensuring we have the funds needed to support and expand projects such as our Community Support Programme. This project enabled people to meet others with similar experiences which was Everything OcuMel UK has achieved has been through sheer dedication and a passion to make a real change to the lives of those affected by this dreadful cancer. We know there is a change coming which gives some hope to our community, but as ever, we will continue until we have a world where people with ocular melanoma can live, and live well.

### **Details of The Independent Examiner**

Tracey Pritchard BA FCA

Member of Chartered Accountant

255 Poulton Road

Wallasey

Merseyside

CH44 4BT

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **Statement of the Directors Trustees' Responsibilities**

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2022**

#### **Method of preparation of accounts - Small company provisions**

The financial statements are set out on pages 13 to 31.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on \_\_\_\_\_ 2022.

MRS C EDWARDS  
Director and Trustee

## OcuMel UK

### **Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022**

I report to the Trustees on my examination of the financial statements of the charitable company on pages 13 to 31 for the year ended 31 March 2022 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 17.

#### **Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report**

As described on page 9, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### **Basis of Independent Examiner's Statement and scope of work undertaken**

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

## OcuMeI UK

### Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

**Signed:-**

Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

This report was signed on \_\_\_\_\_ 2022

## OcuMel UK - Statement of Financial Activities for the year ended 31 March 2022

### Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2022, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
<b>Income &amp; Endowments from:</b>					
Donations & Legacies	A1	28,115	-	<b>28,115</b>	188,750
Charitable activities	A2	497	-	<b>497</b>	199
Other trading activities	A3	43,478	-	<b>43,478</b>	22,161
<b>Total income</b>	<b>A</b>	<b>72,090</b>	<b>-</b>	<b>72,090</b>	<b>211,110</b>
<b>Expenditure on:</b>					
Raising funds	B1	1,058	-	<b>1,058</b>	(1,171)
Charitable activities	B2	128,725	11,106	<b>139,831</b>	202,859
<b>Total expenditure</b>	<b>B</b>	<b>129,783</b>	<b>11,106</b>	<b>140,889</b>	<b>201,688</b>
<b>Net income for the year</b>		<b>(57,693)</b>	<b>(11,106)</b>	<b>(68,799)</b>	<b>9,422</b>
<b>Transfers between funds</b>	<b>C</b>	<b>(344)</b>	<b>344</b>	<b>-</b>	<b>-</b>
<b>Net income after transfers</b>	<b>A-B-C</b>	<b>(58,037)</b>	<b>(10,762)</b>	<b>(68,799)</b>	<b>9,422</b>
<b>Net movement in funds</b>		<b>(58,037)</b>	<b>(10,762)</b>	<b>(68,799)</b>	<b>9,422</b>
<b>Reconciliation of funds:-</b>					
<b>Total funds brought forward</b>		148,545	10,762	<b>159,307</b>	149,885
<b>Total funds carried forward</b>		<b>90,508</b>	<b>-</b>	<b>90,508</b>	<b>159,307</b>

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

**The notes attached on pages 17 to 31 form an integral part of these accounts.**

## OcuMel UK - Statement of Financial Activities for the year ended 31 March 2022

### OcuMel UK - Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use:-

	2022 £	2021 £
Funds generated in the year as detailed in the SOFA	(68,799)	9,422
Resources applied on functional fixed assets	-	(1,444)
Other applications of funds	-	-
<b>Net resources available to fund charitable activities</b>	<b><u>(68,799)</u></b>	<b><u>7,978</u></b>

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 17 to 31 form an integral part of these accounts.

### Movements in revenue and capital funds for the year ended 31 March 2022

#### Revenue accumulated funds

	Unrestricted Funds 2022 £	Restricted Funds 2022 £	Total Funds 2022 £	Last year Total Funds 2021 £
Accumulated funds brought forward	148,545	10,762	159,307	<b>149,885</b>
Recognised gains and losses before transfers	<u>(57,693)</u>	<u>(11,106)</u>	<u>(68,799)</u>	9,422
	<b>90,852</b>	<b>(344)</b>	<b>90,508</b>	<b>159,307</b>
(From)/To unrestricted revenue funds	(344)	344	-	-
<b>Closing revenue funds</b>	<b><u>90,508</u></b>	<b><u>-</u></b>	<b><u>90,508</u></b>	<b><u>159,307</u></b>

#### Summary of funds

	Unrestricted and Designated funds 2022 £	Restricted Funds 2022 £	Total Funds 2022 £	Last Year Total Funds 2021 £
Revenue accumulated funds	90,508	-	<b>90,508</b>	159,307

The notes attached on pages 17 to 31 form an integral part of these accounts.

## OcuMel UK - Statement of Financial Activities for the year ended 31 March 2022

### OcuMel UK Income and Expenditure Account for the year ended 31 March 2022 as required by the Companies Act 2006

	2022 £	2021 £
<b>Income</b>		
Income from operations	72,090	211,110
Investment income		
<b>Gross income in the year before exceptional items</b>	<b>72,090</b>	<b>211,110</b>
<b>Gross income in the year including exceptional items</b>	<b>72,090</b>	<b>211,110</b>
<b>Expenditure</b>		
Charitable expenditure, excluding depreciation and amortisation	109,751	172,879
Depreciation and amortisation	827	727
Fundraising costs	1,058	(1,171)
Governance costs	29,253	29,253
Realised losses on disposals of social investments which are programme related	-	-
<b>Total expenditure in the year</b>	<b>140,889</b>	<b>201,688</b>
<b>Net income before tax in the financial year</b>	<b>(68,799)</b>	<b>9,422</b>
Tax on surplus on ordinary activities	-	-
<b>Net income after tax in the financial year</b>	<b>(68,799)</b>	<b>9,422</b>
<b>Retained surplus for the financial year</b>	<b>(68,799)</b>	<b>9,422</b>

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

**The notes attached on pages 17 to 31 form an integral part of these accounts.**

**OcuMel UK - Balance Sheet as at 31 March 2022**

	SORP		2022	2021
	Note	Ref	£	£
<b>Fixed assets</b>				
Tangible assets	10	A2	583	1,410
<b>Current assets</b>				
Stocks		B1	1,706	1,600
Debtors	12	B2	-	-
Cash at bank and in hand		B4	91,778	158,270
<b>Total current assets</b>			<u>93,484</u>	<u>159,870</u>
<b>Creditors: amounts falling due within one year</b>	13	C1	<u>(3,559)</u>	<u>(1,973)</u>
<b>Net current assets</b>			89,925	157,897
<b>The total net assets of the charity</b>			<u><b>90,508</b></u>	<u><b>159,307</b></u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

<b>Restricted funds</b>				
Restricted Revenue Funds	17	D2	-	10,762
			-	10,762
<b>Unrestricted Funds</b>				
Unrestricted Revenue Funds	17	D3	90,508	148,545
			<u>90,508</u>	<u>148,545</u>
<b>Total charity funds</b>			<u><b>90,508</b></u>	<u><b>159,307</b></u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 12.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

**MRS C EDWARDS**

Trustee

Approved by the board of trustees on \_\_\_\_\_ 2022

The notes attached on pages 17 to 31 form an integral part of these accounts.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

#### 1 Accounting policies

##### *Policies relating to the production of the accounts.*

##### **Basis of preparation and accounting convention**

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

##### **Risks and future assumptions**

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the OcuMel UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

##### **Accounting for deferred income and income received in advance**

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

#### Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

#### ***Policies relating to assets, liabilities and provisions and other matters.***

##### ***Tangible fixed assets***

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

##### **Stocks and work in progress**

Stock is valued at the lower of cost and net realisable value.

##### **Fund Accounting**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

#### 2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

#### 3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

#### 4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

#### 5 Net surplus before tax in the financial year

	2022	2021
	£	£
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	827	727
Trustees' remuneration	28,293	28,293
Pension costs	3,256	2,480
	<u>3,256</u>	<u>2,480</u>

#### 6 Staff costs and emoluments

##### Salary costs

	2022	2021
	£	£
Gross Salaries excluding trustees and key management personnel	44,519	43,459
Employer's operating costs of defined contribution pension schemes	3,256	2,480
Trustees' Remuneration as detailed in note 8	28,293	28,293
<b>Total salaries, wages and related costs</b>	<u><b>76,068</b></u>	<u><b>74,232</b></u>

The average number of full time staff employed in the year was	3	3
The estimated full time equivalent number of all staff employed in the year was	2	2

##### *The estimated equivalent number of full time staff deployed in different activities in the year was:-*

Engaged on charitable activities	2	2
<b>The estimated full time equivalent number of all staff employed as above</b>	<u><b>2</b></u>	<u><b>2</b></u>

The details of remuneration paid to trustees is shown in note 8

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

#### 7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

#### 8 Remuneration and payments to Trustees and persons connected with them

	2022	2021
	£	£
<i>Remuneration payable to trustees or connected persons</i>		
Trustee 1	28,293	28,293
<b>Total remuneration</b>	<b>28,293</b>	<b>28,293</b>

#### 9 Trustees' expenses

No trustee expenses were incurred, either in the current or prior year.

#### 10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
At 1 April 2021	-	3,125	-	3,125
Additions	-	-	-	-
<b>At 31 March 2022</b>	<b>-</b>	<b>3,125</b>	<b>-</b>	<b>3,125</b>
<b>Depreciation</b>				
At 1 April 2021	-	1,715	-	1,715
Charge for the year	-	827	-	827
<b>At 31 March 2022</b>	<b>-</b>	<b>2,542</b>	<b>-</b>	<b>2,542</b>
<b>Net book value</b>				
<b>At 31 March 2022</b>	<b>-</b>	<b>583</b>	<b>-</b>	<b>583</b>
<b>At 31 March 2021</b>	<b>-</b>	<b>1,410</b>	<b>-</b>	<b>1,410</b>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

<i>Prior Year</i>	<b>Land and Buildings</b>	<b>Plant &amp; Machinery</b>	<b>Motor Vehicles</b>	<b>Total</b>
	£	£	£	£
<b>Cost</b>				
01 April 2020	-	1,681	-	1,681
Additions	-	1,444	-	1,444
<b>31 March 2021</b>	<b>-</b>	<b>3,125</b>	<b>-</b>	<b>3,125</b>
<b>Depreciation</b>				
01 April 2020	-	988	-	988
Charge for the year	-	727	-	727
<b>31 March 2021</b>	<b>-</b>	<b>1,715</b>	<b>-</b>	<b>1,715</b>
<b>Net book value</b>				
<b>31 March 2021</b>	<b>-</b>	<b>1,410</b>	<b>-</b>	<b>1,410</b>
<b>31 March 2020</b>	<b>-</b>	<b>693</b>	<b>-</b>	<b>693</b>
<b>11 Stocks &amp; Work in Progress</b>			<b>2022</b>	<b>2021</b>
			£	£
Stocks before write downs			1,706	1,600
			<u>1,706</u>	<u>1,600</u>
<b>12 Debtors</b>			<b>2022</b>	<b>2021</b>
			£	£
Prepayments and accrued income			-	-
<b>13 Creditors: amounts falling due within one year</b>			<b>2022</b>	<b>2021</b>
			£	£
Trade creditors			2,599	1,013
Accruals			960	960
			<u>3,559</u>	<u>1,973</u>
<b>14 Income and Expenditure account summary</b>			<b>2022</b>	<b>2021</b>
			£	£
<b>At 1 April 2021</b>			159,307	149,885
Surplus after tax for the year			(68,799)	9,422
<b>At 31 March 2022</b>			<u>90,508</u>	<u>159,307</u>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

#### 15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

#### 16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2022	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	583	-	-	583
Current Assets	93,484	-	-	93,484
Current Liabilities	(3,559)	-	-	(3,559)
	<b>90,508</b>	<b>-</b>	<b>-</b>	<b>90,508</b>
	<hr/>			
At 1 April 2021	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	1,410	-	-	1,410
Current Assets	149,108	-	10,762	159,870
Current Liabilities	(1,973)	-	-	(1,973)
	<b>148,545</b>	<b>-</b>	<b>10,762</b>	<b>159,307</b>

#### 17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2021	Movement in funds in 2022	Transfers between funds in 2022	Funds carried forward to 2023
	£	£	£	£
	See Note 18			
	£	£	£	£
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	148,545	(57,693)	(344)	90,508
<b>Total unrestricted and designated funds</b>	<b>148,545</b>	<b>(57,693)</b>	<b>(344)</b>	<b>90,508</b>
<b>Restricted funds:-</b>				
Patient booklet	3,000	(3,325)	325	-
Nurse Co-ordinator role	7,762	(7,781)	19	-
<b>Total restricted funds</b>	<b>10,762</b>	<b>(11,106)</b>	<b>344</b>	<b>-</b>
<b>Total charity funds</b>	<b>159,307</b>	<b>(68,799)</b>	<b>-</b>	<b>90,508</b>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2022

#### 18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2022	2022	2022	2022
	£	£	£	£
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	72,090	(129,783)	-	<b>(57,693)</b>
<b>Restricted funds:-</b>				
Patient booklet	-	(3,325)	-	<b>(3,325)</b>
Nurse Co-ordinator role	-	(7,781)	-	<b>(7,781)</b>
	<b>72,090</b>	<b>(140,889)</b>	<b>-</b>	<b>(68,799)</b>

#### 19 The purposes for which the funds

##### **Unrestricted and designated funds:-**

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

##### **Restricted funds:-**

Restricted Revenue Funds:

These funds are restricted and are to be used to design and publish patient booklets.

#### 20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

## OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

*This analysis is classified by conventional nominal descriptions and not by activity.*

### 21 Donations, Grants and Legacies

	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
<b>Donations and gifts from individuals</b>				
Small donations individually less than £1000	22,776	-	<b>22,776</b>	26,768
In Memory	4,379	-	<b>4,379</b>	8,049
<b>Total donations and gifts from individuals</b>	<b>27,155</b>	<b>-</b>	<b>27,155</b>	<b>34,817</b>

All the donations and gifts in the prior year were unrestricted.

#### Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £
<b>Prior year</b>	<b>34,717</b>	<b>100</b>	<b>34,817</b>

	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
<b>Revenue grants from government and public bodies</b>				
National Lottery Funding	-	-	-	25,000
Department for Work & Pension	960	-	<b>960</b>	3,933
Slough Borough Council	-	-	-	5,000
<b>Total public sector revenue grants</b>	<b>960</b>	<b>-</b>	<b>960</b>	<b>33,933</b>

#### Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £
<b>Prior Year</b>	<b>33,933</b>	<b>-</b>	<b>33,933</b>

**OcuMel UK**

**Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015**

	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
<b>Revenue grants and donations from non public bodies</b>				
Taurus Foundation	-	-	-	10,000
medac Pharma LLP	-	-	-	110,000
<b>Total private sector revenue grants</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>120,000</b>
<b>Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis</b>				
	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £	
<b>Prior Year</b>	<b>120,000</b>	<b>-</b>	<b>120,000</b>	

OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

**Total Donations, Grants and Legacies**

		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
<i>Current year</i>		2022	2022	2022	2021
		£	£	£	£
<b>Total Donations, Grants and Legacies</b>	<b>A1</b>	<b>28,115</b>	<b>-</b>	<b>28,115</b>	<b>188,750</b>
<i>Prior year</i>		Unrestricted Funds 2021	Restricted Funds 2021	Prior Year Total Funds 2021	
		£	£	£	
<b>Total Donations, Grants and Legacies</b>	<b>A1</b>	<b>188,650</b>	<b>100</b>	<b>188,750</b>	

**22 Income from charitable activities - Trading Activities**

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
<i>Current year</i>		2022	2022	2022	2021
		£	£	£	£
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		497	-	497	199
<b>Total Primary purpose and ancillary trading</b>		<b>497</b>	<b>-</b>	<b>497</b>	<b>199</b>

**23 Total Income from charitable activities**

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
<i>Current year</i>		2022	2022	2022	2021
		£	£	£	£
Total income from charitable trading		497	-	497	199
<b>Total from charitable activities</b>	<b>A2</b>	<b>497</b>	<b>-</b>	<b>497</b>	<b>199</b>

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

#### 24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Income from fundraising events	43,478	-	43,478	22,161
<b>Total from other activities</b>	<b>43,478</b>	<b>-</b>	<b>43,478</b>	<b>22,161</b>

#### Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	22,161	-	22,161

#### 25 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Gross wages and salaries - charitable activities	36,738	7,781	44,519	43,459
Defined contribution pension costs - charitable activities	3,256	-	3,256	2,480
Travel and Subsistence - Charitable Activities	-	-	-	35
Marketing and advertising of charitable services	5,743	-	5,743	9,234
Charitable activities costs	11,416	3,325	14,741	12,688
Training costs	236	-	236	74
<b>Total direct spending</b>	<b>57,389</b>	<b>11,106</b>	<b>68,495</b>	<b>67,970</b>

All the expenditure in the prior year was unrestricted.

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

<i>Prior Year</i>	Prior Year	Prior Year	Prior Year
	Unrestricted	Restricted	Total Funds
	Funds	Funds	Total Funds
	2021	2021	2021
	£	£	£
Gross wages and salaries - charitable activities	41,221	2,238	<b>43,459</b>
Defined contribution pension costs - charitable activities	2,480	-	<b>2,480</b>
Travel and Subsistence - Charitable Activities	35	-	<b>35</b>
Marketing and advertising of charitable services	9,234	-	<b>9,234</b>
Charitable activities costs	12,588	100	<b>12,688</b>
Training costs	74	-	<b>74</b>
<b>Total direct spending</b>	<b>65,632</b>	<b>2,338</b>	<b>67,970</b>

#### 26 Expenditure on charitable activities- Grant funding of activities

<i>Current Year</i>	Current year	Current year	Current year	Prior Year
	Unrestricted	Restricted	Total Funds	Total Funds
	Funds	Funds	Total Funds	Total Funds
	2022	2022	2022	2021
	£	£	£	£
Grants made to individuals	30,000	-	<b>30,000</b>	<b>80,000</b>
Grants made to organisations	-	-	-	<b>5,000</b>
<b>Total grantmaking costs</b>	<b>30,000</b>	<b>-</b>	<b>30,000</b>	<b>85,000</b>

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

#### 27 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
<b>Premises Expenses</b>				
Rent payable under operating leases	-	-	-	7,710
<b>Administrative overheads</b>				
Telephone, fax and internet	777	-	777	790
Postage	-	-	-	-
Stationery and printing	489	-	489	281
Membership subscriptions	1,258	-	1,258	1,353
Software licences and expenses	3,721	-	3,721	7,127
Sundry expenses	117	-	117	134
Insurance	659	-	659	572
<b>Professional fees paid to advisors other than the auditor or examiner</b>				
Accountancy fees other than examination or audit fees	1,710	-	1,710	1,353
Other legal and professional	2,327	-	2,327	359
<b>Financial costs</b>				
Bank charges	198	-	198	230
Depreciation & Amortisation in total for the period	827	-	827	727
<b>Support costs before reallocation</b>	<b>12,083</b>	<b>-</b>	<b>12,083</b>	<b>20,636</b>
<b>Total support costs - Current Year</b>	<b>12,083</b>	<b>-</b>	<b>12,083</b>	<b>20,636</b>

The basis of allocation of costs between activities is described under accounting policies  
All the expenditure in the prior year was unrestricted.

#### 28 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Independent Examiner's fees	960	-	960	960
Trustees' remuneration	28,293	-	28,293	28,293
<b>Total Governance costs</b>	<b>29,253</b>	<b>-</b>	<b>29,253</b>	<b>29,253</b>

All the expenditure in the prior year was unrestricted.

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

#### 29 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022 £	2022 £	2022 £	2021 £
Total direct spending	<b>B2a</b>	57,389	11,106	<b>68,495</b>	<b>67,970</b>
Total grantmaking costs	<b>B2c</b>	30,000	-	<b>30,000</b>	<b>85,000</b>
Total support costs	<b>B2d</b>	12,083	-	<b>12,083</b>	<b>20,636</b>
Total Governance costs	<b>B2e</b>	29,253	-	<b>29,253</b>	<b>29,253</b>
<b>Total charitable expenditure</b>	<b>B2</b>	<b>128,725</b>	<b>11,106</b>	<b>139,831</b>	<b>202,859</b>
<i>Prior Year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2021 £	2021 £	2021 £	
Total direct spending	<b>B2a</b>	65,632	2,338	<b>67,970</b>	
Total grantmaking costs	<b>B2c</b>	85,000	-	<b>85,000</b>	
Total support costs	<b>B2d</b>	20,636	-	<b>20,636</b>	
Total Governance costs	<b>B2e</b>	29,253	-	<b>29,253</b>	
Movements in provisions and commitments	<b>B2e</b>	-	-	-	
<b>Total charitable expenditure</b>	<b>B2</b>	<b>200,521</b>	<b>2,338</b>	<b>202,859</b>	

#### 30 Expenditure on raising funds and costs of investment management

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022 £	2022 £	2022 £	2021 £
Cost of fundraising activities		1,058	-	<b>1,058</b>	<b>(1,171)</b>
<b>Total fundraising costs</b>	<b>B1</b>	<b>1,058</b>	<b>-</b>	<b>1,058</b>	<b>(1,171)</b>

All the expenditure in the prior year was unrestricted.

**Ocular Melanoma UK**

England & Wales - Charity number 1147506

---

# Accounts

---


Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

OcuMel UK

Report and Accounts

31 March 2021



**OcuMel UK**

**Report and accounts for the year ended 31 March 2021**

**Contents**

	<b>Page</b>
<b>Charity information</b>	1
<b>Trustees' Annual Report</b>	1
<b>Statement of directors' responsibilities</b>	8
<b>Independent Accountant's Report</b>	10
<b><i>Funds Statements:-</i></b>	
Statement of Financial Activities	12
Movements in funds	13
Income and Expenditure account	14
<b>Balance sheet</b>	15
<b>Notes to the accounts</b>	16

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2021**

The Trustees present their Report and Accounts for the year ended 31 March 2021, which also comprises the Directors' Report required by the Companies Act 2006.

#### **Reference and administrative details**

##### ***The charity name.***

The legal name of the charity is:- OcuMel UK.

The charity is also known by its operating name, OcuMel UK.

##### ***The charity's areas operation and UK charitable registration.***

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

##### ***Legal structure of the charity***

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

##### **The principal operating address, telephone number, email and web addresses of the charity are:-**

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address [info@omuk.info](mailto:info@omuk.info)

Web Address [www.ocumeluk.org](http://www.ocumeluk.org)

The registered office of the charity for Companies Act purposes is:-

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2021**

#### **The Trustees in office on the date the report was approved were:-**

Mr Neil Pearce - Chair  
Mrs Giuseppina Gumbs - National Director  
Mrs Joanne Morgan  
Mr Gianfranco De Franco  
Mrs Charlotte Edwards - Treasurer

#### **The following persons served as Trustees during the year ended 31 March 2021 :-**

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-.

<b><i>Name</i></b>	<b><i>Appointed</i></b>	<b><i>Resigned/Retired</i></b>
Mr Neil Pearce - Chair		
Mrs Giuseppina Gumbs - National Director		
Mrs Joanne Morgan		
Mr Gianfranco De Franco		
Mrs Joanna Dallas		21 May 2020
Mrs Tracey Davies		21 May 2020
Michelle Marianne Deans		27 August 2020
Miss Tamara Rimmer		7 September 2020
Mrs Charlotte Edwards - Treasurer		

All the trustees are also members of the charity.

## OcuMel UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2021

#### Objects and activities of the charity

##### *The purposes of the charity.*

###### What is Ocular Melanoma?

Ocular melanoma is a cancer of the eye, including the iris, choroid or ciliary. This can spread (metastasis) to other organs, typically the liver. There are approximately 600 new cases of ocular melanoma in the UK each year and around 50% of patients will develop metastatic diseases within 15 years of the original diagnosis. Of those, 90% will involve the liver. Ocular melanoma that has spread to the liver is incurable, although there are treatments available that have the potential to extend life expectancy and improve quality of life for some patients.

###### Why is OcuMel UK needed?

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming, that patients frequently report feeling totally isolated. OcuMel UK came about to provide both support and a voice for those with rare cancer. We are able to bring sufferers together across the country and provide UK- specific information.

Ocular Melanoma patients are often excluded from melanoma trials, and with no meaningful drug therapy available to treat the condition there has been very little progress made in the last 20 years. OcuMel UK is raising the profile of the disease within the medical community. We hope to improve patients' access to treatment, and eventually to support ocular melanoma research.

Support in other countries can be limited and so information provided through our website is available to all and can be translated to other languages. Support is also given to patients outside the UK on our forums and through our helpline in English. Where country specific information is needed, we can often signpost patients to other community members for assistance.

###### Our aims and objectives

###### Vision:

A world where ocular melanoma sufferers and their families are given the information, support and treatment they need.

###### Mission:

OcuMel UK aims to provide advice, support and information to ocular melanoma sufferers, and to bring the treatment of ocular melanoma in line with more common cancers.

###### Our objectives:

OcuMel UK's charitable objectives are:

1. To primarily promote and protect the physical and mental health of sufferers of ocular melanoma in the United Kingdom through the provision of support, education and practical advice.
2. To advance the education of the public (and in particular, medical professionals) on the subject of ocular melanoma.
3. To promote research for the public benefit on the subject of ocular melanoma and to publish the useful results.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2021**

#### ***The main activities undertaken during the year to further the charity's purpose for the public benefit.***

We provide members and others with current information and non-clinical advice and support through a wide variety of channels. During the year the following were undertaken.

##### **-Helpline**

We provide a telephone Helpline service with response to callers provided by experienced staff and helpline volunteers

##### **-Website**

We operate our informational website [www.ocumeluk.org](http://www.ocumeluk.org) accessible 24 hours per day, delivering information on Ocular Melanoma, its available treatments, and sources of further information.

##### **-Advocacy**

OcuMel UK advocated for our members individually and at a community level. We have done this by issuing surveys and making submissions to relevant bodies on behalf of our membership, so issues that affected patients could be raised. We also produced guides and held several meetings so people were more confident on having a direct input when NICE reviewed a treatment for people with uveal melanoma.

##### **-Emotional Support**

Our members can receive free professional support with a Health Psychologist to ease this diagnosis's impact.

##### **-Bulletins**

We email a monthly newsletter to our members with updates on our work, how to access the services we provide and importantly, we provide information on how people can share their experience to shape future improvements.

##### **-Meetings**

We arrange weekly meetings online for our members to come together and talk through their experience.

##### **-Conference**

This year, we joined forces with the Ocular Melanoma communities in America, Ireland, Canada, and Australia to host the first virtual Eye on a Cure Symposium.

##### **-Rare Community**

OcuMel UK are members of Cancer52 and Genetic Alliance and regularly attend NHS England Cancer Charity meetings so key messages can be communicated to our community.

We are incredibly grateful to our fundraisers and donors for their efforts over this challenging year. It enabled us to continue our work and support people throughout the year.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2021**

#### **Structure, governance and management of the charity**

##### ***The methods used to recruit and appoint new charity trustees.***

###### **Governing Document**

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

###### **Management Committee**

The directors of the company are also charity trustees for the purposes of charity law. Our National Director is also a trustee of the charity, and this has been approved by the Charity Commission, all other Trustees give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 7 to the accounts. Trustees serve for up to three years and may be re-elected at Annual General Meeting.

The Board of Directors, together with the national director, acts as the Management Committee.

###### **Trustee Induction**

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

###### **Organizational Structure**

The Management Committee is responsible for the strategic direction and policy of the charity. The national director has delegated responsibility from the Board for the overall operation of the charity.

###### **Bankers**

CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ

National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House,  
Bairs Road, Middlesex, EN1 1FD

Shawbrook bank, Lutea House, Warley Hill Business Park, The Drive, Great  
Warley, Brentwood, Essex CM13 3BE

## OcuMeI UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2021

#### Financial review

#### *The charity's financial position at the end of the year ended 31 March 2021*

The financial position of the charity at 31 March 2021 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2021	2020
	£	£
<b>Net income</b>	9,422	23,938
Unrestricted Revenue Funds available for the general purposes of the charity	148,545	136,885
Restricted Revenue Funds	10,762	13,000
<b>Total Restricted Funds</b>	10,762	13,000
<b>Total Funds</b>	159,307	149,885

#### *Financial review of the position at the reporting date, 31 March 2021*

The trustees consider the financial performance by the charity during the year to have been satisfactory.

#### *Policies on reserves*

As a small charity with very variable income our main priority is to maintain our long term financial viability. With this in mind, the charity's policy is to build and retain sufficient reserves to meet committed expenditure for 12 months ahead.

#### *Availability and adequacy of assets of each of the funds*

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

## **OcuMel UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2021**

#### ***Plans For the Future***

##### **Summary of plans for the future and the trustees' perspective of the future direction of the charity.**

We strive to improve the care, treatment and support patients receive. We recently employed a nurse to work with the National Director to increase our services. They will work to build stronger links with clinicians, which will, in time, improve the patient experience throughout the UK.

Our team will review our website, soon including a list of clinical trials and a library of research studies relating to ocular melanoma, and will also increase the literature available to patients.

With uncertainty on when large gatherings can safely resume, our annual conference is likely to be held online rather than in person. Virtual events have benefits, but it can be harder to meet others and build friendships. To overcome this, we will be launching a Community Support Programme, where we will recruit and support several Local Ambassadors throughout the UK to host meetings in their local area. We are confident that enabling peer-to-peer support to take place in this way will remove some of the isolation felt.

#### **Details of The Independent Examiner**

Tracey Pritchard BA FCA

Member of Chartered Accountant

255 Poulton Road

Wallasey

Merseyside

CH44 4BT

## OcuMel UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2021

#### Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

**OcuMel UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2021**

**Method of preparation of accounts - Small company provisions**

The financial statements are set out on pages 12 to 29.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 17 December 2021.



**MRS C EDWARDS**  
Director and Trustee

## OcuMel UK

### Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2021

I report to the Trustees on my examination of the financial statements of the charitable company on pages 12 to 29 for the year ended 31 March 2021 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 16.

#### Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 8, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

## OcuMel UK

### Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;


the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

This report was signed on 17/12/2021

OcuMel UK - Statement of Financial Activities for the year ended 31 March 2021

**Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2021, as required by the Companies Act 2006)**

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021 £	2021 £	2021 £	2020 £
<b>Income &amp; Endowments from:</b>					
Donations & Legacies	A1	188,650	100	188,750	76,693
Charitable activities	A2	199	-	199	504
Other trading activities	A3	22,161	-	22,161	88,472
<b>Total income</b>	<b>A</b>	<b>211,010</b>	<b>100</b>	<b>211,110</b>	<b>165,669</b>
<b>Expenditure on:</b>					
Raising funds	B1	(1,171)	-	(1,171)	4,887
Charitable activities	B2	200,521	2,338	202,859	136,844
<b>Total expenditure</b>	<b>B</b>	<b>199,350</b>	<b>2,338</b>	<b>201,688</b>	<b>141,731</b>
<b>Net income for the year</b>		<b>11,660</b>	<b>(2,238)</b>	<b>9,422</b>	<b>23,938</b>
<b>Net income after transfers</b>	<b>A-B-C</b>	<b>11,660</b>	<b>(2,238)</b>	<b>9,422</b>	<b>23,938</b>
<b>Net movement in funds</b>		<b>11,660</b>	<b>(2,238)</b>	<b>9,422</b>	<b>23,938</b>
<b>Reconciliation of funds:-</b>					
	<b>E</b>				
<b>Total funds brought forward</b>		136,885	13,000	149,885	125,947
<b>Total funds carried forward</b>		<b>148,545</b>	<b>10,762</b>	<b>159,307</b>	<b>149,885</b>

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

**The notes attached on pages 16 to 29 form an integral part of these accounts.**

**OcuMel UK - Statement of Financial Activities for the year ended 31 March 2021**

**OcuMel UK - Resources applied in the year ended 31 March 2021 towards fixed assets for Charity use:-**

	2021 £	2020 £
Funds generated in the year as detailed in the SOFA	9,422	23,938
Resources applied on functional fixed assets	(1,444)	(121)
Other applications of funds	-	-
<b>Net resources available to fund charitable activities</b>	<b><u>7,978</u></b>	<b><u>23,817</u></b>

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 16 to 29 form an integral part of these accounts.

**Movements in revenue and capital funds for the year ended 31 March 2021**

**Revenue accumulated funds**

	Unrestricted Funds 2021 £	Restricted Funds 2021 £	Total Funds 2021 £	Last year Total Funds 2020 £
Accumulated funds brought forward	136,885	13,000	149,885	125,947
Recognised gains and losses before transfers	<u>11,660</u>	<u>(2,238)</u>	<u>9,422</u>	<u>23,938</u>
	<b>148,545</b>	<b>10,762</b>	<b>159,307</b>	<b>149,885</b>
<b>Closing revenue funds</b>	<b><u>148,545</u></b>	<b><u>10,762</u></b>	<b><u>159,307</u></b>	<b><u>149,885</u></b>

**Summary of funds**

	Unrestricted and Designated funds 2021 £	Restricted Funds 2021 £	Total Funds 2021 £	Last Year Total Funds 2020 £
Revenue accumulated funds	148,545	10,762	159,307	149,885

The notes attached on pages 16 to 29 form an integral part of these accounts.

**OcuMel UK - Statement of Financial Activities for the year ended 31 March 2021**

**OcuMel UK  
Income and Expenditure Account for the year ended 31 March 2021 as required by the  
Companies Act 2006**

	2021 £	2020 £
<b>Income</b>		
Income from operations	211,110	165,669
Investment income		
<b>Gross income in the year before exceptional items</b>	<b>211,110</b>	<b>165,669</b>
<b>Gross income in the year including exceptional items</b>	<b>211,110</b>	<b>165,669</b>
<b>Expenditure</b>		
Charitable expenditure, excluding depreciation and amortisation	172,879	104,242
Depreciation and amortisation	727	471
Fundraising costs	(1,171)	4,887
Governance costs	29,253	32,131
Realised losses on disposals of social investments which are programme related	-	-
<b>Total expenditure in the year</b>	<b>201,688</b>	<b>141,731</b>
<b>Net income before tax in the financial year</b>	<b>9,422</b>	<b>23,938</b>
Tax on surplus on ordinary activities	-	-
<b>Net income after tax in the financial year</b>	<b>9,422</b>	<b>23,938</b>
<b>Retained surplus for the financial year</b>	<b>9,422</b>	<b>23,938</b>

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

**The notes attached on pages 16 to 29 form an integral part of these accounts.**

**OcuMel UK - Balance Sheet as at 31 March 2021**

	SORP		2021	2020
	Note	Ref	£	£
<b>Fixed assets</b>	A			
Tangible assets	10	A2	1,410	693
<b>Current assets</b>	B			
Stocks		B1	1,600	1,695
Debtors	12	B2	-	22,474
Cash at bank and in hand		B4	158,270	134,009
<b>Total current assets</b>			159,870	158,178
<b>Creditors: amounts falling due within one year</b>	13	C1	<u>(1,973)</u>	<u>(8,986)</u>
<b>Net current assets</b>			157,897	149,192
<b>The total net assets of the charity</b>			<u>159,307</u>	<u>149,885</u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

<b>Restricted funds</b>				
Restricted Revenue Funds	17	D2	10,762	13,000
			10,762	13,000
<b>Unrestricted Funds</b>				
Unrestricted Revenue Funds	17	D3	148,545	136,885
			<u>148,545</u>	<u>136,885</u>
<b>Total charity funds</b>			<u>159,307</u>	<u>149,885</u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 11.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



**MRS C EDWARDS**

Trustee

Approved by the board of trustees on 17 December 2021

The notes attached on pages 16 to 29 form an integral part of these accounts.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

#### 1 Accounting policies

##### *Policies relating to the production of the accounts.*

###### **Basis of preparation and accounting convention**

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

###### **Risks and future assumptions**

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the OcuMel UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

###### **Accounting for deferred income and income received in advance**

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

#### Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

#### *Policies relating to assets, liabilities and provisions and other matters.*

##### *Tangible fixed assets*

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

##### **Stocks and work in progress**

Stock is valued at the lower of cost and net realisable value.

##### **Fund Accounting**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

#### 2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

#### 3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

#### 4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

#### 5 Net surplus before tax in the financial year

	2021	2020
	£	£
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	727	471
Trustees' remuneration	28,293	30,911
Pension costs	2,480	3,347

#### 6 Staff costs and emoluments

##### Salary costs

	2021	2020
	£	£
Gross Salaries excluding trustees and key management personnel	43,459	34,716
Employer's operating costs of defined contribution pension schemes	2,480	3,347
Trustees' Remuneration as detailed in note 8	28,293	30,911
<b>Total salaries, wages and related costs</b>	<b>74,232</b>	<b>68,974</b>

The average number of full time staff employed in the year was	3	3
The estimated full time equivalent number of all staff employed in the year was	2	2

##### The estimated equivalent number of full time staff deployed in different activities in the year was:-

Engaged on charitable activities	2	2
<b>The estimated full time equivalent number of all staff employed as above</b>	<b>2</b>	<b>2</b>

The details of remuneration paid to trustees is shown in note 8

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

#### 7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

#### 8 Remuneration and payments to Trustees and persons connected with them

	2021	2020
	£	£
<i>Remuneration payable to trustees or connected persons</i>		
Trustee 1	28,293	30,911
<b>Total remuneration</b>	<b>28,293</b>	<b>30,911</b>

#### 9 Trustees' expenses

The expenses reimbursed to trustees, or paid directly to third parties, in the current or prior year, was as shown below.

	2021	2020
	£	£
The amount paid directly to third parties on behalf of trustees	-	150
The amount reimbursed to trustees	-	110
	<b>-</b>	<b>260</b>

The nature of the trustees' expenses was :- transport to and from Annual Conference, Conference expenses.

The number of trustees' to whom expenses were reimbursed was :- 2

#### 10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total	Total
	£	£	£	£	£
<b>Cost</b>					
At 1 April 2020	-	1,681	-	1,681	1,681
Additions	-	1,444	-	1,444	1,444
<b>At 31 March 2021</b>	<b>-</b>	<b>3,125</b>	<b>-</b>	<b>3,125</b>	<b>3,125</b>
<b>Depreciation</b>					
At 1 April 2020	-	988	-	988	988
Charge for the year	-	727	-	727	727
<b>At 31 March 2021</b>	<b>-</b>	<b>1,715</b>	<b>-</b>	<b>1,715</b>	<b>1,715</b>
<b>Net book value</b>					
At 31 March 2021	-	1,410	-	1,410	1,410
At 31 March 2020	-	693	-	693	693

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

Prior Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total	Total
	£	£	£	£	£
<b>Cost</b>					
02 April 2019	-	1,560	-	1,560	1,560
Additions	-	121	-	121	121
<b>31 March 2020</b>	<b>-</b>	<b>1,681</b>	<b>-</b>	<b>1,681</b>	<b>1,681</b>
<b>Depreciation</b>					
02 April 2019	-	517	-	517	517
Charge for the year	-	471	-	471	471
<b>31 March 2020</b>	<b>-</b>	<b>988</b>	<b>-</b>	<b>988</b>	<b>988</b>
<b>Net book value</b>					
<b>31 March 2020</b>	<b>-</b>	<b>693</b>	<b>-</b>	<b>693</b>	<b>693</b>
<b>01 April 2019</b>	<b>-</b>	<b>1,043</b>	<b>-</b>	<b>1,043</b>	<b>1,043</b>

#### 11 Stocks & Work in Progress

	2021	2020
	£	£
Stocks before write downs	1,600	1,695
	<u>1,600</u>	<u>1,695</u>

#### Analysis of the carrying value of stocks and work in progress by activities

Activity	Work in Progress		Stocks	
	2021	2020	2021	2020
	£	£	£	£
Charitable activity 1	-	-	1,600	1,695
	<u>-</u>	<u>-</u>	<u>1,600</u>	<u>1,695</u>

#### 12 Debtors

	2021	2020
	£	£
Prepayments and accrued income	-	22,474
	<u>-</u>	<u>22,474</u>

#### 13 Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors	1,013	5,914
Accruals	960	3,072
	<u>1,973</u>	<u>8,986</u>

#### 14 Income and Expenditure account summary

	2021	2020
	£	£
At 1 April 2020	149,885	125,947
Surplus after tax for the year	9,422	23,938
<b>At 31 March 2021</b>	<b><u>159,307</u></b>	<b><u>149,885</u></b>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

#### 15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

#### 16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2021	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £	Total Funds £
Tangible Fixed Assets	1,410	-	-	1,410	1,410
Current Assets	149,108	-	10,762	159,870	159,870
Current Liabilities	(1,973)	-	-	(1,973)	(1,973)
	<b>148,545</b>	<b>-</b>	<b>10,762</b>	<b>159,307</b>	<b>159,307</b>
At 1 April 2020	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £	Total Funds £
Tangible Fixed Assets	693	-	-	693	693
Current Assets	145,178	-	13,000	158,178	158,178
Current Liabilities	(8,986)	-	-	(8,986)	(8,986)
	<b>136,885</b>	<b>-</b>	<b>13,000</b>	<b>149,885</b>	<b>149,885</b>

#### 17 Change in total funds over the year as shown in Note 16, analysed by individual funds

	Funds brought forward from 2020 £	Movement in funds in 2021 See Note 18 £	Transfers between funds in 2021 See Note 0 £	Funds carried forward to 2022 £	Funds carried forward to 2022 £
<b>Unrestricted and designated funds:-</b>					
Unrestricted Revenue Funds	136,885	11,660	-	148,545	148,545
<b>Total unrestricted and designated funds</b>	<b>136,885</b>	<b>11,660</b>	<b>-</b>	<b>148,545</b>	<b>148,545</b>
<b>Restricted funds:-</b>					
Patient booklet	3,000	-	-	3,000	3,000
Nurse Co-ordinator role	10,000	(2,238)	-	7,762	7,762
Patient specific donation	-	-	-	-	-
<b>Total restricted funds</b>	<b>13,000</b>	<b>(2,238)</b>	<b>-</b>	<b>10,762</b>	<b>10,762</b>
<b>Total charity funds</b>	<b>149,885</b>	<b>9,422</b>	<b>-</b>	<b>159,307</b>	<b>159,307</b>

## OcuMel UK

### Notes to the Accounts for the year ended 31 March 2021

#### 18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds	Movement in funds
	2021	2021	2021	2021	2021
	£	£	£	£	£
<b>Unrestricted and designated funds:-</b>					
Unrestricted Revenue Funds	211,010	(199,350)	-	11,660	11,660
<b>Restricted funds:-</b>					
Patient booklet	-	-	-	-	-
Nurse Co-ordinator role	-	(2,238)	-	(2,238)	(2,238)
Patient specific donation	100	(100)	-	-	-
	<b>211,110</b>	<b>(201,688)</b>	<b>-</b>	<b>9,422</b>	<b>9,422</b>

#### 19 The purposes for which the funds

##### **Unrestricted and designated funds:-**

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and ,subject to charity legislation, are free from all restrictions on their use.

##### **Restricted funds:-**

Restricted Revenue Funds:

These funds are restricted and are to be used to design and publish patient booklets and to increase the support available to patients through a specialist nurse.

#### 20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

## OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

*This analysis is classified by conventional nominal descriptions and not by activity.*

### 21 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
<b>Donations and gifts from individuals</b>				
Small donations individually less than £1000	26,668	100	26,768	36,350
In Memory	8,049	-	8,049	5,330
Blackhurst Budd Solicitors	-	-	-	1,000
<b>Total donations and gifts from individuals</b>	<b>34,717</b>	<b>100</b>	<b>34,817</b>	<b>42,680</b>

#### Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2020	2020	2020
	£	£	£
<b>Prior year</b>	<b>42,680</b>	<b>-</b>	<b>42,680</b>

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
<b>Revenue grants from government and public bodies</b>				
National Lottery Funding	25,000	-	25,000	-
Department for Work & Pension	3,933	-	3,933	-
Slough Borough Council	5,000	-	5,000	-
<b>Total public sector revenue grants</b>	<b>33,933</b>	<b>-</b>	<b>33,933</b>	<b>-</b>

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

	Current year Unrestricted Funds 2021 £	Current year Restricted Funds 2021 £	Current year Total Funds 2021 £	Prior Year Total Funds 2020 £
<b>Revenue grants and donations from non public bodies</b>				
Taurus Foundation	10,000	-	10,000	10,000
medac Pharma LLP	110,000	-	110,000	-
<b>Total private sector revenue grants</b>	<b>120,000</b>	<b>-</b>	<b>120,000</b>	<b>10,000</b>

All the grants in the prior year were unrestricted.

#### Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds 2020 £	Prior Year Restricted Funds 2020 £	Prior Year Total Funds 2020 £
<b>Prior Year</b>	<b>-</b>	<b>10,000</b>	<b>10,000</b>

	Current year Unrestricted Funds 2021 £	Current year Restricted Funds 2021 £	Current year Total Funds 2021 £	Prior Year Total Funds 2020 £
<b>Sponsorship</b>				
Immunocore Ltd	-	-	-	10,000
medac Pharma LLP	-	-	-	10,000
Aura Biosciences	-	-	-	4,013
<b>Total sponsorship income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>24,013</b>

#### Sponsorship - Prior Year analysis

	Prior Year Unrestricted Funds 2020 £	Prior Year Restricted Funds 2020 £	Prior Year Total Funds 2020 £
<b>Prior Year</b>	<b>24,013</b>	<b>-</b>	<b>24,013</b>

OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

**Total Donations, Grants and Legacies**

<b>Total Donations, Grants and Legacies</b>	<b>A1</b>	<b>188,650</b>	<b>100</b>	<b>188,750</b>	<b>76,693</b>
---	-----------	----------------	------------	----------------	---------------

All the donations and gifts in the prior year were unrestricted.

*Prior year*

		<b>Unrestricted Funds</b>	<b>Restricted Funds</b>	<b>Prior Year Total Funds</b>
		<b>2020</b>	<b>2020</b>	<b>2020</b>
		<b>£</b>	<b>£</b>	<b>£</b>
<b>Total Donations, Grants and Legacies</b>	<b>A1</b>	<b>66,693</b>	<b>10,000</b>	<b>76,693</b>

**22 Income from charitable activities - Trading Activities**

*Current year*

	<b>Current year Unrestricted Funds</b>	<b>Current year Restricted Funds</b>	<b>Current year Total Funds</b>	<b>Prior Year Total funds</b>
	<b>2021</b>	<b>2021</b>	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>Primary purpose and ancillary trading</b>				
Sale of goods and services in accordance with the charity's objects	199	-	199	504
<b>Total Primary purpose and ancillary trading</b>	<b>199</b>	<b>-</b>	<b>199</b>	<b>504</b>

**23 Total Income from charitable activities**

	<b>Current year Unrestricted Funds</b>	<b>Current year Restricted Funds</b>	<b>Current year Total Funds</b>	<b>Prior Year Total Funds</b>
	<b>2021</b>	<b>2021</b>	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>Total income from charitable trading</b>	<b>199</b>	<b>-</b>	<b>199</b>	<b>504</b>
<b>Total from charitable activities</b>	<b>A2</b>	<b>-</b>	<b>199</b>	<b>504</b>

OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Income from fundraising events	22,161	-	22,161	88,472
<b>Total from other activities</b>	<b>22,161</b>	<b>-</b>	<b>22,161</b>	<b>88,472</b>

Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	88,472	-	88,472

25 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Gross wages and salaries - charitable activities	41,221	2,238	43,459	34,716
Defined contribution pension costs - charitable activities	2,480	-	2,480	3,347
Travel and Subsistence - Charitable Activities	35	-	35	1,299
Marketing and advertising of charitable services	9,234	-	9,234	8,942
Charitable activities costs	12,588	100	12,688	21,889
Training costs	74	-	74	-
<b>Total direct spending</b>	<b>65,632</b>	<b>2,338</b>	<b>67,970</b>	<b>70,193</b>

OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

<i>Prior Year</i>	Prior Year	Prior Year	Prior Year
	Unrestricted	Restricted	Total Funds
	Funds	Funds	Total Funds
	2020	2020	2020
	£	£	£
Gross wages and salaries - charitable activities	34,716	-	34,716
Defined contribution pension costs - charitable activities	3,347	-	3,347
Travel and Subsistence - Charitable Activities	1,299	-	1,299
Marketing and advertising of charitable services	8,942	-	8,942
Charitable activities costs	21,889	-	21,889
<b>Total direct spending</b>	<b>70,193</b>	<b>-</b>	<b>70,193</b>

26 Expenditure on charitable activities- Grant funding of activities

<i>Current Year</i>	Current year	Current year	Current year	Prior Year
	Unrestricted	Restricted	Total Funds	Total Funds
	Funds	Funds	Total Funds	Total Funds
	2021	2021	2021	2020
	£	£	£	£
Grants made to individuals	80,000	-	80,000	-
Grants made to organisations	5,000	-	5,000	-
<b>Total grantmaking costs</b>	<b>85,000</b>	<b>-</b>	<b>85,000</b>	<b>-</b>

Breakdown of Grants made to organisations

<i>Current Year</i>	Current year	Current year	Current year
	Unrestricted	Restricted	Total Funds
	Funds	Funds	Total Funds
	2021	2021	2021
	£	£	£
Melanoma Focus, Guideline Review	5,000	-	5,000
	<b>5,000</b>	<b>-</b>	<b>5,000</b>

## OcuMel UK

### Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

#### 27 Support costs for charitable activities

<i>Current Year</i>	Current year	Current year	Current year	Prior Year
	Unrestricted	Restricted	Total Funds	Total Funds
	Funds	Funds		
	2021	2021	2021	2020
	£	£	£	£
<b>Premises Expenses</b>				
Rent payable under operating leases	7,710	-	7,710	12,672
<b>Administrative overheads</b>				
Telephone, fax and internet	790	-	790	979
Postage	-	-	-	2,791
Stationery and printing	281	-	281	5,669
Membership subscriptions	1,353	-	1,353	747
Software licences and expenses	7,127	-	7,127	6,872
Sundry expenses	134	-	134	84
Insurance	572	-	572	572
<b>Professional fees paid to advisors other than the auditor or examiner</b>				
Accountancy fees other than examination or audit fees	1,353	-	1,353	1,886
Other legal and professional	359	-	359	1,619
<b>Financial costs</b>				
Bank charges	230	-	230	158
Depreciation & Amortisation in total for the period	727	-	727	471
<b>Support costs before reallocation</b>	<b>20,636</b>	<b>-</b>	<b>20,636</b>	<b>34,520</b>
<b>Total support costs - Current Year</b>	<b>20,636</b>	<b>-</b>	<b>20,636</b>	<b>34,520</b>

The basis of allocation of costs between activities is described under accounting policies  
All the expenditure in the prior year was unrestricted.

#### 28 Other Expenditure - Governance costs

<i>Current Year</i>	Current year	Current year	Current year	Prior Year
	Unrestricted	Restricted	Total Funds	Total Funds
	Funds	Funds		
	2021	2021	2021	2020
	£	£	£	£
Independent Examiner's fees	960	-	960	960
Trustees' remuneration	28,293	-	28,293	30,911
Trustees' expenses	-	-	-	260
<b>Total Governance costs</b>	<b>29,253</b>	<b>-</b>	<b>29,253</b>	<b>32,131</b>

All the expenditure in the prior year was unrestricted.

OcuMel UK

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

29 Total Charitable expenditure

		Current year	Current year	Current year	Prior Year
		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
<i>Current Year</i>		2021	2021	2021	2020
		£	£	£	£
Total direct spending	<b>B2a</b>	65,632	2,338	67,970	70,193
Total grantmaking costs	<b>B2c</b>	85,000	-	85,000	-
Total support costs	<b>B2d</b>	20,636	-	20,636	34,520
Total Governance costs	<b>B2e</b>	29,253	-	29,253	32,131
<b>Total charitable expenditure</b>	<b>B2</b>	<b>200,521</b>	<b>2,338</b>	<b>202,859</b>	<b>136,844</b>
<i>Prior Year</i>		Prior Year	Prior Year	Prior Year	
		Unrestricted Funds	Restricted Funds	Total Funds	
		2020	2020	2020	
		£	£	£	
Total direct spending	<b>B2a</b>	70,193	-	70,193	
Total support costs	<b>B2d</b>	34,520	-	34,520	
Total Governance costs	<b>B2e</b>	32,131	-	32,131	
<b>Total charitable expenditure</b>	<b>B2</b>	<b>136,844</b>	<b>-</b>	<b>136,844</b>	

30 Expenditure on raising funds and costs of investment management

		Current year	Current year	Current year	Prior Year
		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
<i>Current Year</i>		2021	2021	2021	2020
		£	£	£	£
Cost of fundraising activities		(1,171)	-	(1,171)	4,272
Fundraising trading costs		-	-	-	615
<b>Total fundraising costs</b>	<b>B1</b>	<b>(1,171)</b>	<b>-</b>	<b>(1,171)</b>	<b>4,887</b>

All the expenditure in the prior year was unrestricted.